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 2 
Abstract 
 
 
Background and Aims: Improving survival in pulmonary arterial hypertension 
depends on developing novel therapies which target pulmonary vascular 
remodelling. MicroRNAs (miRNAs) are post-transcriptional modulators of gene 
expression, many of which have been shown to influence signalling pathways and 
cell processes which control pulmonary vascular remodelling. However, miRNAs 
have complex and often contradictory actions on these mechanisms, and better 
understanding of these complexities is needed. MicroRNA-155 has been linked to 
factors which drive pulmonary hypertension (PH) including TGF-b/BMP signalling, 
inflammation, vasoactive mediators and cellular response to hypoxia. Through 
manipulation of miR-155 levels, this thesis aims to establish if the pathobiology of 
PH can be better understood by examining links to some of these factors or others 
such as p38 MAPK signalling, and to evaluate the in vitro and in vivo effects of 
downregulating miR-155, with regards to pulmonary vascular remodelling. 
 
Methods and results: Downregulation of miR-155 either via a knockout (KO) 
mouse model, or pharmacological antagonism in vitro, was studied in the hypoxic 
model of PH. In vitro, downregulation of miR-155 prevented the proliferative and 
migratory response of pulmonary artery fibroblasts (PAFs) to hypoxia. This was 
seen both in PAFs from the KO mice, and in rat PAFs treated with antimiR-155. 
Reduced hypoxic phosphorylation of p38 MAPK was also seen in both models. 
Hypoxic activation of Smad5, a member of the TGF-b/BMP family, was greater in 
KO mouse PAFs than in wild type (WT) controls. In vivo, hypoxic KO mice had a 
lower right ventricular systolic pressure than WT controls. Right ventricular 
hypertrophy did not develop in the KO mice exposed to hypoxia, and hypoxia-
driven vascular remodelling was prevented in the KO mice. 
 
Conclusions: Downregulation of miR-155 conveys a protective effect against PH. 
Remodelling mechanisms are attenuated in vitro, and this translates to an in vivo 
effect. p38 MAPK has been shown by others to control the hypoxic proliferation of 
PAFs, so the reduced hypoxic phosphorylation of p38 MAPK in this study may partly 
explain these results. Manipulation of miR-155 in PH should be studied further to 
fully elucidate the mechanisms behind these findings. 
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1.1 Pulmonary Hypertension 
 
1.1.1 General Introduction 
 
The focus of this thesis is a condition called pulmonary hypertension (PH). Rather 
than representing a single disease entity, this is a widely-encompassing term 
applied to a collection of diseases with the unifying feature of raised pulmonary 
artery pressure (PAP). This results in increased pulmonary vascular resistance 
(PVR) and subsequent right ventricular (RV) failure and premature death. 
Clinically, patients present with worsening breathlessness, peripheral oedema, 
chest pain and exertional syncope.  
 
Much progress has been made in recent years with regards understanding 
pulmonary vascular biology and, in particular, with the development of disease-
targeted treatments for pulmonary arterial hypertension (PAH). However there 
remains an unmet clinical need as demonstrated by an ongoing unacceptably high 
mortality rate. This chapter will briefly outline the definition, classification and 
treatment of PH, as well as explore the current understanding of the pathogenesis 
of the condition. 
 
1.1.2 Definition of pulmonary hypertension 
 
PH is defined as the presence at right heart catheterisation (RHC) of a persistent 
resting mean PAP of greater than 25mmHg [1]. However, this is simply a 
haemodynamic measurement rather than a diagnosis and gives no insight into the 
underlying aetiology of the condition. Further measurements made at RHC help to 
characterise the nature of PH. The presence of an elevated pulmonary artery 
wedge pressure (PAWP), i.e. >15mmHg, indicates post-capillary PH, which is due 
to left heart disease. PH with a normal PAWP is termed pre-capillary PH and 
describes all other classes of PH. This is outlined in table 1-1 [2]. PVR is also 
calculated from measurements taken at RHC. An elevation of PVR to greater than 
3 Wood units is necessary for the diagnosis of PAH, and is a feature of other causes 
of PH which may also respond to disease-targeted therapy. 
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Definition Characteristics Clinical Group 
Pulmonary hypertension 
(PH) 
mPAP ³ 25mmHg 
 
All 
Pre-capillary PH mPAP ³ 25mmHg 
PAWP £ 15mmHg 
1. Pulmonary arterial hypertension 
3. PH due to lung disease and/or 
hypoxia 
4. Chronic thromboembolic 
pulmonary hypertension 
5. PH with unclear multifactorial 
mechanisms 
Post-capillary PH mPAP ³ 25mmHg 
PAWP > 15mmHg 
2. PH due to left heart disease 
 
Table 1-1 Haemodynamic definitions of pulmonary hypertension 
Adapted from “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary 
hypertension” by Galie, N. et al. Eur Heart J, 2016. 37(1): p. 67-119. mPAP, mean pulmonary 
artery pressure; PAWP, pulmonary artery wedge pressure. 
 
 
1.1.3 Classification and diagnosis of pulmonary hypertension 
 
Following an outbreak of PH due to the appetite suppressant Aminorex in the 
1970s, a forum of international experts was called by the World Health 
Organisation. Here, a simple classification and haemodynamic definition of PH was 
agreed upon. These forums have continued at regular intervals, with further 
refinements of the classification system based on haemodynamic and pathological 
characteristics, as well as management strategies.  The most recent forum in Nice, 
France in 2013 produced a comprehensive overview of the clinical and 
pathophysiological facets of PH [3].  
 
The clinical classification of PH, as agreed at the Nice symposium, is outlined in 
table 1-2 [4]. This divides PH into five discrete groups, of which groups 1, 4 and 5 
(PAH, chronic thromboembolic PH, and miscellaneous, respectively) are the 
groups which are currently shown to derive benefit from specific PH-targeted 
therapies. These groups are the broad focus of this thesis, and in particular PAH. 
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Updated Classification of Pulmonary Hypertension 
1. Pulmonary arterial hypertension 
1.1 Idiopathic PAH 
1.2 Heritable PAH 
1.2.1 BMPR2 
1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 
1.2.3 Unknown 
1.3 Drug and toxin induced 
1.4 Associated with 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary 
haemangiomatosis 
1’’ Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction 
and congenital cardiomyopathies 
3. Pulmonary hypertension due to lung diseases and/or 
hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive 
pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung disease 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial 
mechanisms 
5.1 Haematologic disorders: chronic haemolytic anaemia, 
myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, 
thyroid disorders 
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic 
renal failure, segmental PH 
 
Table 1-2 Clinical classification of pulmonary hypertension 
Adapted from “Updated clinical classification of pulmonary hypertension” by Simonneau, G. et al. 
J Am Coll Cardiol, 2013. 62(25 Suppl): p. D34-41. 
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In order to determine the exact aetiology of pulmonary hypertension, and 
therefore assess the appropriateness of disease-targeted therapy, patients should 
undergo thorough investigation by a specialist pulmonary vascular team. 
Unfortunately, a major hurdle to reaching this stage is the often subtle and non-
specific nature of the symptoms reported by patients, which require a high index 
of clinical suspicion on the part of the physician undertaking the initial 
assessment. Often, the average time from symptom onset to diagnosis can be as 
long as 4 years [5]. To help improve this, an argument could be made that 
screening programmes are warranted for those at high risk, such as patients with 
connective tissue disease, congenital heart disease and HIV. 
 
The evaluation of a patient with suspected pulmonary hypertension should aim to 
confirm the diagnosis of PH, as well as clarifying its aetiology and severity. As a 
screening tool, echocardiography adds weight to a clinical suspicion of PH, as well 
as evaluating the possibility of left heart disease. However, the gold standard test 
is right heart catheterisation, which confirms the haemodynamics that define PH. 
Further assessment should include computed tomography, pulmonary function 
testing, magnetic resonance imaging and ventilation/perfusion scintigraphy (VQ). 
 
The process is laid out in the 2015 ESC/ERS guidelines [2] and summarised in figure 
1-1. 
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Figure 1-1 Simplified algorithm for the investigation of suspected pulmonary hypertension 
Adapted from “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary 
hypertension” by Galie, N. et al. Eur Heart J, 2016. 37(1): p. 67-119. ECG, electrocardiograph; 
PFTs, pulmonary function tests; CXR, chest radiograph; HRCT, high resolution computed 
tomography; ABGs, arterial blood gases; CTPA, computed tomography pulmonary angiography; 
CTEPH, chronic thromboembolic PH; WU, Wood units; CTD, connective tissue disease; CHD, 
congenital heart disease; HIV, human immunodeficiency virus. 
 
 
1.1.4 Epidemiology and prognosis of pulmonary arterial 
hypertension 
 
PAH remains a rare disease. Recent indications are that incidence is in the range 
of 5-10 cases per million adults, with a prevalence of 15-60 per million [2]. Modern 
registries from several countries, including France, the United States and the UK, 
reflect these numbers [6-8]. These registries also indicate a female 
preponderance towards PAH, ranging from 65% to 80% of patients being female. 
Over time, there have been changes in the results collected by these registries 
[9]. The landmark NIH registry in the US, which collected data between 1981 and 
1988, recorded the mean age at diagnosis as 36 years [10]. This has increased to 
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50-65 years in modern registries, reflecting the changing clinical profile of 
patients. Several possible explanations for this increasing age of patients at 
diagnosis have been suggested. These include increased physician and patient 
awareness and understanding of the disease; an increase in the frequency of non-
invasive screening such as by echocardiography; and improvements in the clinical 
diagnosis of PAH, as it’s possible that in the past patients with comorbidities such 
as lung disease or left heart disease may have been misclassified [11].  
 
Importantly, and likely as a consequence of disease-targeted therapies, PAH 
patients are living longer. Median survival has increased from 2.8 years in the NIH 
registry [10] to 7 years in the REVEAL database [12], with survival at one year 
improved from 68% in the NIH registry to over 90% in the UK registry [8]. Despite 
these improvements, PAH remains a progressive disease. The consequences of the 
vascular remodelling that characterises the disease are an increase in pulmonary 
vascular resistance and increased work for the right ventricle, leading to RV 
hypertrophy. The RV ultimately dilates and fails, culminating in premature death 
[13]. Current treatments can delay this, mostly by ameliorating the pulmonary 
vasoconstriction that accompanies the process. However, treatments which 
prevent or reverse remodelling are desperately needed.  
 
1.1.5 Current treatments for pulmonary arterial hypertension 
 
Over the last 20 years, the introduction of disease-targeted drugs has 
revolutionised PAH treatment. These primarily act as pulmonary vasodilators 
through smooth muscle relaxation and hence reduction of right ventricular 
overload. Their effect on pulmonary vascular remodelling, the key underlying 
pathological process, is minimal. Unfortunately, this means that the condition will 
still progress, albeit at a reduced rate, ultimately resulting in premature death. 
 
The currently available targeted therapies exert their vasodilatory effect on the 
pulmonary circulation via three distinct pathways. These pathways, and the drug 
classes which act on them, are the nitric oxide pathway (phosphodiesterase-5 
inhibitors and soluble guanylate cyclase stimulators); the endothelin pathway 
(endothelin receptor antagonists); and the prostacyclin pathway (prostanoids). 
Epoprostenol, a short-acting pulmonary vasodilator delivered as a continuous IV 
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infusion, falls into this last group. It was the first agent used to directly treat PAH 
and was shown to improve exercise capacity and survival [14]. Whilst multiple 
clinical trials have shown the functional and haemodynamic improvement with 
other PAH-specific drugs since epoprostenol, the only other drug to show a clear 
survival benefit is the endothelin receptor antagonist macitentan [15]. 
 
Response to treatment should be regularly assessed by improvement in symptoms 
and WHO functional class, as well as exercise capacity, typically using the six-
minute walk test. Combination therapy with drugs from two or more classes can 
be used when initial improvement is inadequate or, increasingly, from the point 
of diagnosis in those with severe disease. Supportive medications such as 
diuretics, oxygen, anticoagulants and digoxin also remain important in the general 
management of PAH patients. If response to treatment remains poor despite 
optimal combination therapy and supportive measures, then lung transplantation 
should be considered. 
 
This section highlights the need for improved disease-specific treatments for PAH. 
Drugs which target the underlying pulmonary vascular remodelling process are the 
next step in advancing the management for these patients, and understanding the 
pathobiology of PAH is key to this. 
 
  
1.2 Pathobiology of pulmonary hypertension 
 
1.2.1 The normal pulmonary circulation 
 
The pulmonary circulation is a low pressure, high flow circuit with thin-walled 
compliant vessels, and a relatively under-perfused vascular bed in normal 
conditions at rest. These features allow it to cope with significant changes in 
volume and flow, such as with exercise-induced increases in cardiac output, 
without a dramatic increase in pressure, which the thin-walled right ventricle 
cannot generate. 
 
Between the main pulmonary artery and the capillary bed there are 15 divisions 
of the pulmonary arterial system [16]. Whilst there are distinct differences in 
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these vessels as the network progresses from proximal to distal, the vessel wall 
largely has the same structure. There are three distinct cellular layers in the wall 
of a normal pulmonary artery. Working from the outside of the vessel in, the first 
of these is the adventitia. This layer consists of fibroblasts and extracellular 
matrix, along with the vasa vasorum which are blood vessels arising from the 
systemic bronchial circulation. The middle layer, or media, largely comprises of 
smooth muscle cells. The intima is the innermost layer and is made up of 
endothelial cells. Separating these layers are external and internal elastic 
laminae, respectively.  
 
The proximal vessels in the pulmonary arterial tree (divisions 15-13) have a medial 
smooth muscle layer that is generally thinner than that found in the medium size 
vessels (divisions 12-4). In contrast, the smaller vessels and arterioles, especially 
those with a diameter less than 100µm, usually lack a smooth muscle layer [17]. 
These smaller vessels are contiguous with the pulmonary capillary network which 
forms the interface with the alveolar network. It is here where the main function 
of the pulmonary circulation occurs, namely gas exchange. 
 
1.2.2 The pulmonary circulation in pulmonary hypertension 
 
The pathobiology of pulmonary hypertension is complex and multifaceted. The 
key pathological processes are vasoconstriction, pulmonary vascular remodelling, 
loss of smaller distal pulmonary vessels (vascular pruning) and vascular thrombosis 
in situ [18]. These processes occur to a varying extent in all forms of pulmonary 
hypertension, depending on the exact aetiology. For example, in chronic 
thromboembolic pulmonary hypertension (CTEPH), extensive thrombosis, both in 
proximal and distal vessels, is a core component of the condition’s pathogenesis. 
In contrast, thrombosis in PAH tends to be present inconsistently and in smaller 
arterioles [19].  
 
Vasoconstriction undoubtedly plays a part in the development of PH. This may be 
driven by factors such as hypoxia or intracellular calcium levels. Clinically, 
vasoconstriction is thought to be a principal feature in a distinct subset (<10%) of 
idiopathic PAH patients who demonstrate a vasoreactive phenotype. This is 
assessed at right heart catheterisation by way of acute pulmonary vasodilator 
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testing, for example with inhaled nitric oxide. Patients in this subset show a 
significant response to vasoreactivity testing, often with near-normalisation of 
PAP and PVR, and benefit from calcium channel blockers. [20]. 
 
Various vasoactive mediators have also been identified and the majority of current 
treatments target these pathways. However, the fact that these treatments 
largely do not improve survival suggests that vasoconstriction is not the main 
factor in the development of PAH in the majority of cases. There is often 
significant overlap between vasoconstriction and vascular remodelling, with many 
molecular mechanisms and signalling pathways involved in both processes. These 
are explored later in this chapter. 
 
Overall, it is now clear that pulmonary vascular remodelling is the dominant 
pathological factor in severe pulmonary hypertension. Characterised by cellular 
hypertrophy, proliferation and migration, remodelling causes restriction of blood 
flow and hence an increase in pulmonary vascular resistance and increased RV 
afterload. After initial adaptation to these conditions through processes including 
RV hypertrophy, the right heart ultimately decompensates and fails, resulting in 
death. 
 
The exact triggers of these processes are unknown, but it is a widely held 
consensus that PAH is caused by a combination of environmental, inflammatory 
and genetic factors which interact in a “multiple-hit” mechanism [21]. 
 
1.2.3 Pulmonary vascular remodelling: key cellular and signalling 
mechanisms 
 
In health, the structure of the pulmonary arterial wall is kept constant by a 
balance between apoptosis and proliferation of adventitial fibroblasts, smooth 
muscle cells in the medial layer, and endothelial cells. In PAH, this balance 
becomes disrupted leading to adventitial and intimal thickening and 
muscularisation of smaller distal vessels which were previously non-muscularised. 
These processes are the main drivers of pulmonary vascular remodelling, a 
hallmark feature of PAH [18]. The result of this is luminal narrowing, and this in 
turn leads to elevated pulmonary vascular resistance. 
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Pulmonary vascular remodelling is a complex process and our understanding of it 
remains incomplete. All layers and cell types of the vessel wall are involved, and 
a range of molecular signalling pathways are involved. These will now be 
individually considered. 
 
1.2.3.1 Pulmonary artery fibroblasts 
 
Pulmonary artery fibroblasts (PAFs) are the most abundant cellular component of 
the adventitia. They play an important role in providing mechanical support to 
the vessel wall by producing extracellular matrix (ECM). However, evidence has 
emerged over recent years to show that their role is much more active than just 
forming a supporting framework. They are important for both the initiation and 
propagation of pulmonary vascular remodelling. In hypoxic animal models of PH, 
there is evidence of early adventitial remodelling and increased fibroblast 
proliferation [22]. There is also evidence from animal models that the most 
significant proliferative response to hypoxia of all vessel wall cell types is that of 
the adventitial fibroblast [23]. 
 
Activation of fibroblasts by numerous stimuli leads to their differentiation into 
myofibroblasts. Amongst these simulants are growth factors such as TGF-b, which 
stimulates the expression of a-smooth muscle actin and collagen production [24, 
25] facilitating the transformation towards a myofibroblast phenotype. 
Inflammatory cytokines including IL-6 also promotes this transition [26], as does 
hypoxia [27, 28]. These myofibroblasts demonstrate contractile functions and 
have the ability to migrate through the vessel wall, contributing to the distal 
muscularisation of previously non-muscularised vessels [29-31]. 
 
Fibroblasts are the principle regulators of the adventitial extracellular matrix. The 
production of ECM increases substantially in response to injurious stimuli leading 
to an accumulation of proteins including collagen, elastin, osteopontin and 
fibronectin. This results in vascular remodelling, with vessel stiffening and 
decreased compliance [32, 33]. Activated fibroblasts have also been shown to 
release growth factors and reactive oxygen species that have paracrine effects on 
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nearby smooth muscle cells and endothelial cells, further stimulating proliferation 
and propagating vascular remodelling [34]. 
 
In summary, PAFs show an early proliferative response to hypoxia; their 
transformation into myofibroblasts causes vessel muscularisation; they cause an 
increase in ECM deposition; and they stimulate the proliferation of other vessel 
wall cell types. These features make PAFs key players in pulmonary vascular 
remodelling. 
 
1.2.3.2 Pulmonary artery smooth muscle cells 
 
The medial compartment of the pulmonary vascular wall responds to hypoxia, 
inflammatory cytokines and other stimuli to cause further structural change of the 
vessel. Pulmonary artery smooth muscle cells (PASMCs) proliferate, hypertrophy, 
migrate and produce matrix proteins in response to these stimuli, causing medial 
hypertrophy and the muscularisation of small arteries/arterioles [35]. In 
remodelling, imbalance between proliferation and apoptosis of PASMCs results in 
medial thickening. This is supported by evidence from human PAH, with increased 
resistance of PASMCs to apoptotic stimuli such as bone morphogenetic protein 
(BMP)-2 and -7, in comparison to normal PASMCs [36]. 
 
In PASMCs, cytosolic Ca2+ levels are important determinants of cellular 
proliferation, migration and contraction. Elevated Ca2+ levels result in the 
activation of various transcription factors, such as nuclear factor of activated T-
cells (NFAT), which promotes PASMC proliferation [37, 38]. Contraction of smooth 
muscle is an important component of pulmonary vasoconstriction. This is also 
driven by elevated Ca2+ levels, ultimately initiating the interaction of myosin 
filaments with actin filaments in a process known as crossbridge cycling. 
 
The influx of Ca2+ into PASMCs can be controlled by voltage-gated calcium channels 
and non-selective cation channels such as transient receptor potential channels 
(TRPC). In patients with PAH, there is increased expression of TRPC proteins, 
which suggest one way in which cellular calcium homeostasis may be upset in PAH 
[39]. The homeostasis of intracellular potassium also has a knock-on effect on 
calcium levels, as K+ ions control cell membrane depolarisation, which activates 
 28 
voltage-gated calcium channels. In PAH, the down-regulation of voltage-sensitive 
potassium channels (Kv) in PASMCs results in an increase of intracellular K+ ions 
and therefore depolarisation of the cell membrane [40]. 
 
1.2.3.3 Pulmonary artery endothelial cells 
 
The intimal layer of pulmonary arteries is predominantly formed by pulmonary 
artery endothelial cells (PAECs). The function of the normal endothelium is to act 
as a semipermeable membrane and regulate vascular tone, cellular proliferation 
and coagulation. Given its constant contact with blood, the endothelium is the 
component of the vessel wall that is most readily exposed to damage from shear 
stress, toxins and inflammation, and therefore is primely positioned to play a key 
role in the early stages of remodelling. Increased PAEC proliferation along with 
increased collagen deposition and inward migration of myofibroblasts contribute 
to neointimal thickening and hence pulmonary vascular remodelling [41]. 
 
Another important feature of vessel remodelling is the formation of plexiform 
lesions, which in part are due to disorganised proliferation and apoptosis of PAECs 
[42].  Most commonly seen in IPAH and less commonly in other forms of PAH, these 
lesions contain PAECs that are monoclonal [43]. This implies a semi-malignant 
process, a theory which is further supported by the decreased expression in 
plexiform lesions of peroxisome proliferator-activated receptor-g (PPAR-g), which 
has anti-proliferative and pro-apoptotic functions and is speculated to function as 
a tumour suppressor gene [44]. PPAR-g has also previously been shown to convey 
a protective effect in experimental PH [45]. 
 
Endothelial dysfunction further propagates the pathogenesis of PH through 
dysregulation of various vasoactive mediators. These include endothelin-1 and 
thromboxane, which are pro-proliferative and induce vasoconstriction, and nitric 
oxide and prostacyclin, which are vasodilators and anti-proliferative. 
 
1.2.3.4 Endothelin-1 
 
Endothelin-1 (ET-1) is primarily a potent vasoconstrictor and pro-proliferative 
peptide which, in the lungs, is principally released by endothelial cells [46]. 
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Elevated levels of ET-1 have been found in both patients with PAH and animal 
models [47, 48] and endothelin receptor antagonism in an animal model of chronic 
hypoxic PH demonstrated a protective effect [49]. This benefit has successfully 
been translated to humans, and endothelin receptor antagonists (ETRAs) are now 
an important treatment modality for patients, leading to improvements in quality 
of life and exercise tolerance. 
 
ET-1 exerts its effects via the G-protein coupled receptors ETA and ETB. These 
receptors vary not only in their distribution within the pulmonary vasculature, but 
also the effects they mediate. The detrimental effects of ET-1, such as 
vasoconstriction and cell proliferation are primarily as a result of its action on ETA 
receptors, which are found on both PASMCs and PAFs [50, 51].  
 
The role of ETB receptors however is more complex. They are principally found on 
endothelial cells, but to a lesser extent on PASMCs and PAFs. ET-1 acts on 
endothelial cells via the ETB receptor to stimulate the release of the vasodilators 
nitric oxide and prostacyclin [51, 52]. ETB receptors also contribute to the 
clearance of ET-1, likely due to the internalisation of the ET-1/ETB receptor 
complex intracellularly after binding [53]. Conversely, the binding of ET-1 on ETB 
receptors located on smooth muscle cells appears to result in pulmonary 
vasoconstriction [54]. It is also becoming clear that the roles of the ETA and ETB 
receptors is different in disease, compared with healthy conditions. For example, 
the vasoconstrictive role of ETB receptors may be more pronounced in PH [55].  
This may be as a result of the upregulation of ETB receptors, which has been 
identified in the distal pulmonary vessels of PAH patients [50]. It is this complexity 
of the role of the ETB receptor which has led to debate about whether ETRAs which 
are selective for the ETA receptor, or those which target both ETA and ETB, confer 
the greater therapeutic benefit. 
 
1.2.3.5 Nitric oxide 
 
In the pulmonary circulation, nitric oxide (NO) is derived primarily from 
endothelial cells through the actions of endothelial nitric oxide synthase (eNOS) 
on L-Arginine [56]. It exerts its effects on adjacent PASMCs in a paracrine fashion 
via activation of soluble guanylate cyclase (sGC) and a subsequent increase of the 
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secondary messenger cyclic guanosine monophosphate (cGMP). Ultimately this 
results in relaxation of smooth muscle cells and vasodilation. NO also has an 
inhibitory effect on the proliferation and migration of PASMCs. In the pulmonary 
circulation, the action of phosphodiesterase type 5 (PDE5) depletes cGMP, 
terminating the effect of NO. 
 
The importance of the NO system to the pulmonary vasculature has been 
demonstrated in both humans and animals. Genetic knockout of eNOS in mice 
results in reduced cGMP and causes PH. This is partially ameliorated by restoration 
of the gene through adenoviral transfection [57] [58]. The administration of 
specific NOS antagonists to healthy humans results in an elevated pulmonary 
vascular resistance [59], whilst the pulmonary vessels from the explanted lungs of 
patients with IPAH show reduced eNOS levels [60]. The use of inhaled NO as a part 
of the diagnostic process to assess pulmonary vasoreactivity in humans has already 
been discussed, and in intensive care units NO can be used for therapeutic benefit. 
 
The clinical translation of these findings has led to the manipulation of the NO 
pathway as a treatment for PH. This is most well established with the PDE5 
inhibitors including sildenafil and tadalafil. However, stimulators of sGC are now 
used in clinical practice. Riociguat, the first drug in this family, is effective in 
both PAH [61] and CTEPH [62]. 
 
1.2.3.6 Prostacyclin and Thromboxane A2 
 
Prostacyclin (PGI2) is a metabolite of arachidonic acid, produced by PAECs through 
the action of cyclooxygenase and subsequently prostacyclin synthase. It acts via 
the G-coupled IP receptor, causing an increase in cyclic adenosine monophosphate 
(cAMP), the consequences of which are vasodilation, decreased platelet 
aggregation and inhibited proliferation of smooth muscle cells [63]. In animal 
models, administration of prostanoids has led to reversal of markers of vascular 
remodelling [64] [65].  Thromboxane A2 is another metabolite of arachidonic acid 
with effects that are antagonistic to prostacyclin, inducing vasoconstriction and 
platelet aggregation. Imbalance between these two compounds contributes to 
endothelial dysfunction and, in human PAH, PAECs have been shown to have 
decreased levels of prostacyclin synthase and increased levels of thromboxane A2  
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[66]. These observations led to the development of prostacyclin analogues for the 
treatment of PAH, with intravenous epoprostenol still considered the gold 
standard therapy [2].  
 
1.2.4 Pulmonary vascular remodelling: other important factors 
 
1.2.4.1 TGF-b/BMP signalling 
 
The transforming growth factor beta (TGF-b) superfamily is a complex signal 
transduction pathway, components of which play an important role as regulators 
of cardiovascular development and disease, including PAH [67]. The family is 
composed of more than 60 members, including the TGF-b ligands themselves, 
activins and bone morphogenetic proteins (BMPs) [68]. All the ligands in this 
superfamily exert their effect through a similar signalling cascade. This involves 
the activation of type I and type II receptors, followed sequentially by receptor-
specific cytoplasmic transcription factors, known as Smads, which then 
translocate to the nucleus and modulate gene function. 
 
Among the type I receptors are TGF-bR1, activin receptor-like kinase 1 (ALK-1, 
also known as ACVRL-1), BMPR1a and BMPR1b. Type II receptors include TGF-bR1 
and BMPR2. Both receptor types are trans-membrane serine/threonine kinases, 
which exist in their resting state in pairs i.e. homodimers. When the specific ligand 
binds, a heterotetrameric receptor complex forms. This comprises of two 
homodimers, one each of type I and type II receptors. The type II receptors are 
constitutively active so, when the ligand binds, these then phosphorylate the 
inactive type I receptors. This results in activation of the cytoplasmic Smads. 
 
Three Smad sub-groups exit: the receptor-regulated Smads (R-Smads including 
Smad1, Smad2, Smad3, Smad5 and Smad8); the common mediator Smad (Co-Smad 
i.e. Smad4) and inhibitory Smads (I-Smads, including Smad6 and Smad7) [68-70]. 
Once the type I receptor has been activated, exactly which R-Smads it recruits 
and phosphorylates depends on which ligand has bound to which combination of 
receptors. It should be noted that the same ligand can induce differing signalling 
pathways and hence responses, depending on exactly which receptors comprise 
the activated complex. 
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It is recognised that TGF-bR1 recruits Smad2/3 through the action of a TGF-b 
ligand. However, TGF-b ligands can also act via ALK-1 to activate Smad1/5/8. The 
BMP ligands, acting through the BMPR1a or BMPR1b, will also recruit Smad1/5/8. 
Once the R-Smads have been phosphorylated they dissociate from the receptor 
complex and translocate to the nucleus, facilitated by their interaction with the 
co-Smad, Smad4. One of the main targets of TGF-b/BMP signalling are the 
inhibitor of differentiation (Id) proteins. Once transcription factors bind to these 
proteins they are prevented from binding to DNA, preventing cellular 
differentiation and promoting proliferation.   
 
The TGF-b/BMP signalling pathway is illustrated in figure 1-2. 
 
 
 
Figure 1-2 The TGF-b/BMP signalling pathway 
Ligands from the TGF-b superfamily bind to the heterotetrameric receptor complex in the cell 
membrane, resulting in the recruitment of R-Smads. Facilitated by Smad4, R-Smads then 
translocate to the nucleus where they regulate gene expression. indicates phosphorylation. 
Replicated with permission from “Transforming Growth Factor b/Bone Morphogenic Protein 
Signaling in Pulmonary Arterial Hypertension: Remodeling Revisited” by Eickelberg, O. and Morty, 
R. E. Trends in Cardiovascular Medicine, 2007, 17(8): p263-9. 
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TGF-b/BMP signalling has been shown to regulate PASMC and PAEC proliferation, 
differentiation and migration. As explained above, the processes are complex and 
depend on which combination of receptors are activated. Activation of TGF-bR1 
by TGF-b inhibits PAEC proliferation and migration via the phosphorylation of 
Smad2/3. However, when TGF-b activates ALK-1, PAEC proliferation and migration 
is promoted via the phosphorylation of Smad1/5/8 [71, 72]. 
 
BMPs have also been shown to signal in a Smad-independent manner. When Smad 
signalling is supressed, such as through a mutation in the BMPR2 receptor, BMP 
ligands can signal via mitogen-activated protein kinase (MAPK) pathways. 
Specifically, this is through activation of TGF-b activated kinase 1 (TAK1), a 
member of the MAPKKK family. Ordinarily TAK1 is bound to BMPR2, but this 
relationship is reduced in the presence of a BMPR2 mutation, freeing TAK1 and 
making it accessible for BMP signalling. TAK1 activation by BMPs leads to the 
phosphorylation of p38 MAPK which, in PASMCs with a BMPR mutation, results in 
increased cellular proliferation. This suggests an important interaction between 
the BMP and MAPK signalling pathways [73, 74]. 
 
1.2.4.2 Genetic factors 
 
Reports of families with PH, which date back to at least 1954, indicate a clear 
underlying genetic susceptibility to the disease [75, 76]. The most common 
genetic mutations in PAH are those within the gene encoding the bone 
morphogenetic protein receptor 2 (BMPR2), a key component of the TGF-b/BMP 
signalling family. Over 300 such mutations have been identified to date, and these 
are found in approximately 75% of cases of heritable PAH (HPAH) and 25% of 
apparently idiopathic PAH cases [77]. BMPR2 mutations are inherited in an 
autosomal dominant fashion, however there is incomplete penetrance of 
approximately 20% [78], meaning that up to 80% of carrier will not be affected, 
and lending some weight to the “multiple-hit” hypothesis of causation of PAH. 
The development of HPAH, like IPAH, has a marked female predominance and 
exhibits genetic anticipation, suggesting that younger females are at increased 
risk of developing HPAH. 
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Animal models have been developed in an effort to emulate PH caused by BMPR2 
mutations. A knockout (KO) mouse model that is heterozygous for BMPR2 displays 
decreased signalling through Smad1/5/8 in PASMCs [79]. Phenotypically, it 
exhibits only mild PH with distal vascular remodelling but without RV hypertrophy. 
A second stimulus, such as hypoxia, is necessary for significant PH to develop. 
 
Alternative pathogenic mutations arising from the TGFb/BMP family are also 
linked to the development of HPAH. These are especially prominent in individuals 
affected by hereditary haemorrhagic telangiectasia (HHT), with the most well 
documented mutations affecting the activin receptor-like kinase-1 (ALK-1) gene 
and the endoglin gene [80, 81]. 
Recently, a novel mutation in the gene encoding potassium channel subfamily K 
member 3 (KCNK3) was identified as responsible for PAH in members of the same 
family in which a previously known PAH-causing mutation could not be identified 
[82]. This mutation results in loss of function of the potassium channel, although 
this could be remedied by pharmacological manipulation. 
 
1.2.4.3 The role of p38 MAPK 
 
Mitogen-activated protein kinases (MAPKs) constitute a pivotal signalling pathway 
that allows cells to process a diverse variety of external stimuli and orchestrate 
an appropriate response. They regulate an array of cell functions including 
differentiation, proliferation and apoptosis [83]. Once an external stimulus 
activates a cell membrane receptor complex, a signalling cascade is triggered by 
sequential phosphorylation. This cascade consists of at least three core 
components (MAP3K, MAPKK and MAPK) and ultimately exerts its effect through 
phosphorylation of cytosolic substrate proteins or by activating nuclear 
transcription factors [84]. 
 
Among the distinct subgroups of MAPKs are the extracellular signal-regulated 
kinases (ERK) family; the c-Jun N-terminal kinases (JNK) family and the p38 MAPK 
family. The p38 family (of which there are 4 isomers - a, b, g, d) is of particular 
interest as it has been shown to be activated by hypoxia and specific inflammatory 
cytokines and growth factors that are important in PH [85].  
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Our laboratory has an ongoing core interest in the interactions between hypoxia, 
p38 MAPK and pulmonary artery fibroblasts, and the contribution of these 
interactions to the pathogenesis of PH. Among the notable findings, from our 
group and others, which link these three factors are: 
 
• Exposure to acute hypoxia results in increased cellular proliferation of 
normal rat, human and bovine PAFs [86, 87]. 
• PAFs from chronic hypoxic animals (CHPAFs) which are cultured in normoxia 
are constitutively hyperproliferative compared to normal PAFs, suggesting 
a phenotypic switch [88-90]. 
• p38 MAPK plays an essential role in the proliferation of PAFs in acute 
hypoxia, and is constitutively upregulated in CHPAFs. Inhibition of p38MAPK 
can prevent or reverse the hyperproliferative effect in both acute and 
chronic hypoxia [89-91] 
• The effects of acute hypoxia on fibroblasts and the p38 MAPK pathway are 
specific to the pulmonary circulation, with no effect seen in systemic 
fibroblasts [92]. 
• Hypoxia-induced upregulation of p38 MAPK causes endothelial dysfunction 
and decreased nitric oxide, which can be reversed by inhibition of p38 MAPK 
[93]. 
• p38 MAPK is important in BMPR2 mutations. PASMCs with BMPR2 mutations 
have ineffective Smad signalling, and p38 MAPK signalling becomes active 
[74]. 
• Only the a and g isoforms of p38 MAPK are phosphorylated in hypoxia-
exposed PAFs [94]. 
• Antagonism of the a isoform of p38 MAPK with a novel clinically available 
drug reverses PH in the chronic hypoxic and monocrotaline animal models. 
Given the presence of elevated levels of phosphorylated p38 MAPK and p38 
MAPKa in pulmonary vessels from IPAH patients, this novel drug has 
potential as a therapeutic agent  [95]. 
 
When considered together, these observations provide cohesive evidence that 
that p38 MAPK is an important signalling mechanism in the development of 
pulmonary vascular remodelling. It also provides a route through which further 
exploration of the pathobiology of PH can be explored. 
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1.2.4.4 Inflammation and pulmonary hypertension 
 
Evidence for the role of inflammatory processes in the initiation and propagation 
of PH and pulmonary vascular remodelling is growing continually. A clear 
connection between inflammatory conditions/autoimmunity and PAH exists in the 
form of connective tissue disease associated PAH. Conditions such as systemic 
sclerosis and systemic lupus erythematosus (SLE) are established causes of PAH 
and as well as responding to PAH-targeted therapy, there is a role for 
immunosuppression in SLE-PAH [96, 97]. An early link between inflammation and 
plexiform lesion was identified [42], and more recently, increased levels of 
inflammatory cells, such as macrophages, mast cells, T cells and B cells, in the 
adventitia of IPAH patients lends further evidence [98].  
 
Cytokines such as IL-6 are produced by a number of immune cells. Elevated levels 
of cytokines, including IL-6, are found in the circulation of IPAH, familial PAH and 
systemic sclerosis patients and have been noted to correlate with survival [99, 
100]. Serum IL-6 levels also correlate to the severity of PH in patients with chronic 
obstructive pulmonary disease (COPD) [101]. It is also implicated in animal models 
of PH, with evidence of increased migration of PASMCs, suggesting a contribution 
to pulmonary vascular remodelling [102, 103]. Overall, the role of inflammation 
in PAH clearly warrants further investigation. 
 
1.2.4.5 Hypoxia: vasoconstriction and remodelling 
 
Hypoxia is the condition of insufficient oxygen supply to maintain normal function 
of cells, tissues or organisms. It is one of the most common aetiologies of 
pulmonary hypertension. How the systemic and pulmonary circulations respond to 
acute hypoxia differs. In the systemic circulation, hypoxia results in vasodilation 
and an increase of oxygen supply to tissues. In the pulmonary circulation however, 
it results in hypoxic pulmonary vasoconstriction (HPV). This can be considered an 
adaptive response, to shunt blood away from inadequately ventilated areas of the 
lung and hence improve ventilation-perfusion (VQ) mismatch. However, it is also 
one of the key pathological processes in PH. 
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Several possible mechanisms are postulated to be possible for HPV. Increased 
intracellular calcium concentrations in PASMCs is partly caused by influx through 
voltage gated calcium channels and non-specific cationic channels [39]. This 
promotes cellular contraction and vasoconstriction. Simultaneously, hypoxia 
results in altered activity of potassium channels, increasing membrane 
depolarisation resulting in further cell contraction [40]. The paracrine function of 
ET-1 released from neighbouring PAECs, along with reduced eNOS activity, can 
further promote the vasoconstriction, and this his has been discussed earlier in 
this chapter. 
 
Whilst HPV is a typical response to acute hypoxia, the pulmonary circulation 
undergoes remodelling when hypoxia is chronic [104]. The effect of chronic 
hypoxia on individual cell types in the pulmonary vessels wall has been considered 
previously. Many of the effects of chronic hypoxia are mediated through hypoxia 
inducible factor 1 (HIF-1), a ubiquitous regulator of the cellular response to 
hypoxia. HIF-1 is a heterodimeric protein composed of individual a and b 
components. Under normal oxygen concentrations HIF-1a is degraded, however 
this degradation is reduced in hypoxia with stabilisation of HIF-1a [105]. HIF-1a 
subsequently translocates to the nucleus, regulating the transcription of various 
genes that are influential in PH such as ET-1, calcium channels and VEGF [106]. 
The importance of HIF-1 is further highlighted by the finding that transgenic mice 
heterozygous for HIF-1a, whilst phenotypically normal under baseline conditions, 
are protected against hypoxia-induced PH [107, 108]. Hypoxia is undoubtedly an 
important factor in PH, both due to acute HPV and chronic hypoxic remodelling. 
 
1.2.4.6 Serotonin 
 
Interest in the “serotonin hypothesis of pulmonary hypertension” arose with the 
outbreak of anorexigen-associated PAH. These agents, such as Aminorex, are 
substrates for the serotonin transporter (SERT), causing increased extracellular 
serotonin [109]. The conversion of L-trytophan to 5-hydroxy-L-tyrptophan through 
the action of tryptophan hydroxylase (TPH) is an early step in the synthesis of 
serotonin (5-HT) [110]. Increased expression of pulmonary arterial endothelial 
TPH-1 has been observed in PAH patients and serotonin derived from the 
endothelium can act on neighbouring PASMCs in a paracrine fashion [111]. In vitro, 
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serotonin activates serotonin receptors on human PASMCs to induce cellular 
proliferation and migration [112]. The incubation of rat PAFs with serotonin 
stimulates cell proliferation and migration, as well as causing increased expression 
of a-SMA, a marker of cellular differentiation into myofibroblasts [113]. 
 
The complex interaction between serotonin, gender and female sex hormones has 
been implicated in the pathogenesis of PAH. The overexpression of SERT in male 
mice has no effect on indicators of PH such as RV systolic pressure or pulmonary 
vascular remodelling. Female mice overexpressing SERT, however, do develop PH 
which becomes even more marked following exposure to chronic hypoxia [114]. 
Ovariectomy leads to attenuation of PH in the SERT+ mice, however the PH 
phenotype is re-established by administration of 17b oestradiol to both the 
hypoxic and normoxic SERT+ve mice. The increased prevalence of PAH in females 
may in part be explained by the serotonin hypothesis. 
 
 
1.3 Animal models of pulmonary hypertension 
 
Understanding the pathobiology of PAH is vital to the development of new 
therapies for the disease. Animal models are important tools in elucidating the 
exact molecular mechanisms involved, and although no perfect model exists which 
perfectly replicates human disease, there are a number of well-established and 
newer models. The chronic hypoxic and monocrotaline models are the most 
extensively studied, however they lack the complex plexiform arteriopathy seen 
in severe human disease. Modifications of these classic models often incorporates 
a second “hit”, therefore theoretically more closely reflecting the pathogenesis 
and histological findings seen in PAH. By developing models which more closely 
replicate the human disease, research should lead to the discovery of more 
potential treatments which are not just successful in preclinical trials, but which 
also translate to benefits in humans. 
 
1.3.1 Chronic hypoxia model 
 
Humans and animals that reside at high altitude develop elevated PA pressures 
and RV hypertrophy [115, 116]. In addition, chronic hypoxia leads to the PH 
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associated with various conditions including COPD, interstitial lung disease and 
sleep apnoea (Group 3 in the PH classification). Acute and chronic hypoxia 
influence the development of PH as outlined above, and the relative ease with 
which hypoxic conditions can be reproduced makes it an appealing model to study. 
Rodents exposed to hypobaric hypoxia are most commonly studied in PAH. This 
technique maintains the oxygen fraction in the air, but reduces atmospheric 
pressure, replicating conditions at high altitude. Rats exposed to hypobaric 
hypoxia for 2 weeks develop elevated PA pressures, RV hypertrophy, muscularised 
and thickened distal vessels, and vascular pruning relatively quickly [117]. 
However, the response varies across species and strains. The hypoxic mouse model 
for example develops haemodynamic changes but remodelling is much less marked 
[118, 119]. Plexiform lesions are not seen in this model, and removal of the 
hypoxic stimulus causes disease reversal, suggesting it is a less robust model. 
 
1.3.2 Monocrotaline rat model 
 
Monocrotaline (MCT) is a pyrrolizidine alkaloid, derived from the seeds of the 
Crotalaria spectabilis plant. It is most commonly utilised in rats, and is 
administered as a single subcutaneous or intraperitoneal injection in a pro-drug 
form, which is then metabolised to its active form by cytochrome P450 CYP3A in 
the liver [120]. Pulmonary hypertension and pulmonary vascular remodelling 
typically develop over 1 to 2 weeks and progressively worsen [121]. Although not 
fully understood, monocrotaline is thought to produce its effect through direct 
toxicity of its metabolites on the lung [122]. There is activation of proliferative 
and anti-apoptotic factors and along with dysregulated NO signalling [123, 124], 
arising from damage to the endothelial cell membrane and loss of essential 
membrane proteins including caveolin-1 [125].  Once again, plexiform lesions are 
not seen [126]. Death frequently occurs after treatment with monocrotaline, 
however this may be due to hepatic damage or other toxic effects rather than PH 
[127]. 
 
1.3.3 SU5416/Hypoxia model 
 
This model was developed in an attempt to more realistically recapitulate human 
PAH, and reinforces the “multiple-hit” hypothesis in disease development. It 
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involves the administration of the VEGF receptor-2 inhibitor SU5416 (“Sugen”) to 
rats or mice, which are then exposed to chronic hypoxia. Vascular endothelial 
growth factor (VEGF) is involved in the regulation of endothelial cell function and 
maintenance [128], and administration of the VEGFR-2 inhibitor combined with 
chronic hypoxia produces a severe form of PH, with extensive remodelling and, 
importantly, the development of plexiform lesions [129, 130]. This model, and 
others which more closely resemble the complex remodelling processes seen in 
humans, offer promising new tools for elucidating the mechanisms behind PAH. 
 
 
1.4 MicroRNAs 
 
1.4.1 Introduction 
 
MicroRNAs (miRNAs, miRs) are small, single strands of non-coding RNA, consisting 
of 22-25 nucleotide bases, which act as post-transcriptional regulators of gene 
expression. They bind to the 3’ untranslated region (UTR) of complementary 
target mRNA, resulting in translational repression or causing degradation of the 
mRNA [131, 132]. The first miRNA, named lin-4, was identified in 1993 in the 
nematode Caenorhabditis elegans [133, 134]. It was the discovery of a second 
miRNA in 2000, and the realisation that it was conserved across many species, that 
triggered the subsequent exponential growth in miRNA research [135, 136]. 
According to version 21 of the online database miRBase (released June 2014), 
microRNAs have been recognised in over 200 species so far, with more than 2500 
mature miRNAs identified in humans, and many more predicted. MicroRNA-mRNA 
interactions are complex. A single miRNA is capable of regulating hundreds of 
genes and conversely, a single gene can be regulated by multiple miRNAs [137]. 
As a result of this, miRNAs can help with understanding the disease aetiology and 
signalling pathways, even if they are not utilised directly as therapeutic agents.  
 
1.4.2 MicroRNA biogenesis 
 
The biogenesis of miRNAs involves multiple steps, which are illustrated in figure 
1-3. The process begins in the nucleus with the transcription of the miRNA gene 
by RNA polymerase II, creating the primary miRNA (pri-miRNA) [138]. This primary 
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transcript can be over 1000 bases long and will often include the sequences for 
multiple mature miRNAs (polycistronic) [131, 139]. Cleavage of the pri-miRNA 
then occurs to form the pre-miRNA, a stem loop molecule ~70 nucleotides long. 
This step is controlled by the action of Drosha, a nuclear RNase III enzyme, which 
forms a complex with the DiGeorge syndrome critical region gene 8 (DGCR8), a 
double-stranded RNA binding protein [140, 141]. After processing by Drosha and 
DGCR8, the pre-miRNA binds to Exportin 5, a nucleo-cytoplasmic transport factor, 
which facilitates its export to the cytoplasm.  
 
 
 
 
Figure 1-3 The biogenesis of miRNA 
The biogenesis of microRNAs begins in the nucleus with the translation of the pri-miRNA. A series 
of cleavage steps by various enzymes in both the nucleus and the cytoplasm before the mature 
miRNA is integrated into the RISC which aids binding with, and subsequent repression or 
degradation of, the target mRNA. Replicated with permission from [142] “MicroRNAs in pulmonary 
arterial hypertension: pathogenesis, diagnosis and treatment.” Journal of the American Society of 
Hypertension, 2015 9(3): p221-34. 
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In the cytoplasm, the pre-miRNA undergoes a further cleavage step by the 
cytoplasmic RNase III endonuclease enzyme termed Dicer. This creates a 
temporary double-stranded miRNA duplex. Through the action of helicases, the 
duplex is separated into the guide strand (the mature miRNA) and the passenger 
strand, which is usually degraded. The mature miRNA then binds to the Argonaut 
protein (Ago), a component of the RNA-induced silencing complex (RISC).  
 
1.4.3 MicroRNA mechanisms of action and regulation 
 
Once loaded into the RISC, the mature miRNA then binds to the target mRNA. The 
manner in which this happens is thought to influence the mechanism by which the 
miRNA regulates gene expression. The binding process involves the so-called “seed 
sequence” of the miRNA, found on the 5’ end of the miRNA and comprising of 
nucleotides 2-8. Broadly speaking, if there is complete complementarity between 
the miRNA “seed sequence” and the 3’ UTR of the target mRNA (based on Watson-
Crick pairing), then mRNA degradation results. Partial complementarity, however, 
usually leads to repressed translation of the mRNA. In various animals species, 
most miRNA-mRNA binding tends to be imperfect, resulting in features such as 
nucleotide bulging [143]. This suggests that mRNA repression is the primary mode 
of action in animal species. 
 
Although likely less important, alternative mechanisms of binding have been 
identified. These mechanisms help to improve overall recognition of target mRNA 
by miRNA, and include 3’-end pairing, where there is complementarity between 
the 3’ ends of both the miRNA and its target [144]. Binding between the 5’ ends 
has also been reported (which may actually lead to enhanced translation) [145], 
and to “centred sites” where the midsection of the miRNA binds [146]. 
 
Many miRNAs, along with their targets, are widely conserved across species, 
whereas some are specific to a small number of animal or plant species. Even if a 
miRNA is widely conserved, it may not be expressed to the same extent in 
different species, and this may also vary within a specific species, based on its 
stage of development [147]. Furthermore, these regulators of mRNA expression 
are themselves subject to regulation through mechnisms such as methylation, RNA 
editing and the action of single nucleotide polymorphisms (SNPs) [148]. 
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1.4.4 MicroRNAs as therapeutic targets 
 
As miRNAs are so intricately involved in the regulation of gene expression, they 
clearly have the potential to modify signalling pathways and hence influence 
disease processes. This makes techniques which manipulate miRNA levels 
attractive as prospective therapies. Manipulation of miRNA levels can be achieved 
by two broad strategies. Expression of miRNAs can be enhanced by a miR-mimic 
which substitutes for a downregulated miRNA. Levels can also be suppressed by 
an antimiR, an oligonucleotide with a sequence complementary to the miRNA 
being targeted, permitting binding and inactivation.  
 
One advantage of using miRNAs as treatments could be the ability to target 
multiple genes within a network, potentially enhancing the therapeutic effect. 
Their relatively small size is attractive with regards ease of delivery into tissues. 
However, manipulation of miRNA levels with miR-mimics or antimiRs also poses 
challenges. Targeting the specific tissue where the miRNA imbalance exists can 
prove difficult. This therefore creates issues with off-target effects. This could be 
amplified by the ability of a single microRNA to have many targets. Toxicity may 
also arise as a consequence of an immune response to either the miR-mimic or 
antimiR, or the carrier agent used to get it into its target tissue. Despites the 
potential hurdles, miRNAs are being investigated as therapies in human clinical 
trials, such as with the miR-122 inhibitor Miravirsen in hepatitis C [149]. 
 
 
1.5 MicroRNAs in pulmonary hypertension 
 
The development of the lungs, and maintenance of their homeostasis is dependent 
on miRNAs [150, 151], and microRNAs have been shown to be implicated in the 
pathogenesis of a wide range of pulmonary diseases, including lung cancer, COPD 
and pulmonary fibrosis [152, 153]. With regards pulmonary hypertension, many 
causative stimuli are able to modify the expression of miRNA in vascular cells. The 
dysregulation of miRNAs influences disease processes that are important in 
vascular remodelling, including cell proliferation, apoptosis and migration via a 
multitude of signalling pathways. What is also clear is that miRNA expression is 
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dynamic, with variable expression as the disease progresses [154]. Several of the 
more notable miRNA that have recently been studied in PAH will now be reviewed. 
 
1.5.1 miR-21 
 
Research conducted into miR-21 in PAH suggests it plays an important role, 
although some findings are apparently contradictory. Upregulation of miR-21 has 
been demonstrated in response to hypoxia in human PAECs [155] and human 
PASMCs [156]. In vitro, treatment of human PASMCs with antimir-21 results in 
reduced proliferation and migration in response to hypoxia [156]. Conversely, 
exogenous overexpression of miR-21 using a miR mimic enhances the proliferation 
of human PASMCs [157]. Upregulation of miR-21 has also been noted in lung tissue 
from various animal models including chronic hypoxic mice [157] as well as IL-6 
overexpressing mice and the SU5416/hypoxia mouse model [155]. Increased mir-
21 staining has been demonstrated by in situ hybridisation in the distal pulmonary 
vessels from PAH patients [155]. In vivo, downregulation of miR-21 has been shown 
to both prevent and reverse the development of PH in mice exposed to chronic 
hypoxia [157]. Taken together, these results suggest that miR-21 plays a 
contributory role in the development of PH. However, evidence that contradicts 
these findings has been seen in miR-21 knockout mice exposed to SU5416/hypoxia. 
These mice develop a pronounced PH phenotype compared to their wild type 
controls, suggesting that miR-21 is protective [155]. There is also contradictory 
evidence in the monocrotaline rat model, with Caruso et al finding downregulation 
of miR-21 [154], but Parikh and colleagues demonstrating upregulation [155]. It is 
clear that the role of miR-21 in the development of PH is complex. Some of these 
contradictory finding may be explained by the variety of cells, species and PH 
models examined, and overall it may not be possible to directly compare them. 
 
1.5.2 miR-124 
 
Downregulation of miR-124 has been observed in various animal models of PH, as 
well as in human IPAH samples. PAFs from calves with hypoxia-induced PH and 
PAFs from patients with IPAH show lower levels of miR-124, along with a 
proliferative and migratory phenotype [158]. Augmentation of miR-124 levels in 
bovine and human PAFs reduces PAF proliferation and migration, and 
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pharmacological reduction of miR-124 in control PAFs causes a proliferative 
phenotype [158]. Reduced expression of miR-124 has also been observed in human 
PASMCs exposed to hypoxia and in lung tissue from mice with chronic hypoxia-
induced PH [159]. NFAT is an important transcription factor in the regulation of 
cell proliferation and apoptosis. miR-124 has been shown to have an inhibitory 
effect on the NFAT pathway by regulating NFAT phosphorylation and its nuclear 
translocation. Over expression of miR-124 inhibits PASMC proliferation and 
promote cellular differentiation possibly through repression of NFAT [159]. miR-
124 therefore could be considered as anti-proliferative and pro-differentiation. 
 
1.5.3 miR-145 
 
miR-145 is organised in a bicistronic cluster with miR-143, with the pair 
transcribed from a common pri-miRNA. Both miRNAs are highly expressed in SMCs 
and fundamental in SMC physiology. In the systemic circulation miR-145 has been 
postulated to have a protective role, as carotid arteries with neointimal formation 
have reduced miR-145 levels, and miR-145 over-expression reduces neointimal 
formation in a balloon injury model [160]. However, a converse role for miR-145 
has been identified in the pulmonary circulation. Upregulation of miR-145 in 
PASMCs, pulmonary arteries, and whole lung homogenate from PAH patients has 
been demonstrated [161]. This is corroborated by findings from lung and RV tissue 
from chronic hypoxic mice. In vivo data has shown a reduction in PH in hypoxic 
mice that under-express miR-145 through both transgenic and pharmacological 
methods [161]. Elevated miR-143/145 expression has also been identified in 
vascular concentric lesions in human PAH samples, suggesting a tendency towards 
vessel muscularisation. 
 
1.5.4 miR-204 
 
One of the first miRNAs to be associated with pulmonary vascular remodelling was 
miR-204. Downregulation of miR-204 in chronic hypoxic and monocrotaline rat 
models of PH has been proven [154] [162]. The treatment of monocrotaline rats 
with nebulised miR-204 mimics decreased pulmonary artery pressures on echo, 
and reduced RV wall thickness [162]. Decreased expression of miR-204 has also 
been seen in human PAH, correlating with disease severity as indicated by 
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pulmonary vascular resistance [162]. Human PAH-PASMCs also display greater 
proliferation and resistance to apoptosis, compared with control PASMCs. These 
findings were replicated in normal hPASMCs treated with a miR-204 antagomiR. 
The pro-proliferative/anti-apoptotic phenotype observed with miR-204 
downregulation appears to be regulated via the STAT3-NFAT pathway, with 
increased STAT3 and NFATc2 expression identified in PAH-PASMCs and PAH lung 
tissue. ET-1 and other factors important in the pathogenesis of PAH activate 
STAT3, a transcription factor which binds to miR-204 causing its downregulation. 
This results in an increase in miR-204 target gene SHP2, and subsequently a further 
increase in STAT3, creating a positive feedback loop and a more severe PH 
phenotype. STAT3 directly induces NFATc2 expression, which is necessary for 
ongoing PAH-PASMC proliferation and resistance to apoptosis [162]. 
 
1.5.5 miR-150 and miR-26a – potential biomarkers in PAH 
 
The first miRNA to be suggested as an independent predictor of survival in PAH is 
miR-150. A small cohort study of PAH patients identified 58 miRNAs with plasma 
levels that were altered in PAH. Of these, miR-150 was most downregulated, and 
it was subsequently shown to correlate with survival. Levels of miR-150 were also 
found to be decreased in the lungs of monocrotaline rats [163]. A further potential 
candidate as a biomarker for PAH is miR-26a [164]. Reduced plasma levels of miR-
26a have been shown in both monocrotaline rats and PAH patients compared with 
controls. Expression of miR-26a in lung and RV tissue from monocrotaline rats has 
also been demonstrated as substantially lower, correlating with haemodynamic 
parameters and RV hypertrophy. A positive correlation between miR-26a levels 
and the six-minute walk distance has also been demonstrated. 
 
 
1.6 MicroRNA-155 and links to pulmonary hypertension 
 
1.6.1 Introduction to miR-155 
 
MicroRNA-155 is a ‘typical multifunctional miRNA’ with roles in numerous 
biological processes and diseases including inflammation, immunity, 
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haematopoiesis, solid cancers and viral infection [165]. The precursor for miR-155 
is processed from the B-cell Integration Cluster (BIC) gene, which is located on 
chromosome 21. The BIC gene itself was first identified due to its role in avian 
viral-induced lymphomas [166]. Further links between BIC/miR-155 and 
haematological malignancies have been identified, including the role miR-155 
plays in diffuse large B cell lymphoma (DLBCL) [167, 168]. The role of miR-155 in 
the activation of the Epstein-Barr virus and the subsequent role it plays in EBV-
related malignancies has also been established [169]. The effect of miR-155 on 
TGF-b/BMP signalling pathway, and in particular Smad5, will now be explored, 
along with other potential links between miR-155 and pulmonary hypertension 
pathobiology. 
 
1.6.2 miR-155 and TGF-b pathway 
 
MicroRNA-155 has been linked to the TGF-b pathway through its roles in the 
development of DLBCL and in the pathobiology of the Epstein-Barr virus related 
malignancies. Overexpression of miR-155 is associated with aggressive forms of 
DLBCL [170, 171]. Using unbiased genome-wide screening tools, Rai et al [167] 
identified that miR-155 binds to the 3’ UTR of the Smad5 gene, making Smad5 a 
direct target of miR-155. Ectopic overexpression of miR-155 in DLBCL cell lines 
resulted in downregulation of Smad5 and, conversely, inhibiting miR-155 with an 
antimiR led to elevated Smad5 levels. This confirms the inverse correlation 
between miR-155 and Smad5. DLBCL cells overexpressing miR-155 were also found 
to be resistant to the growth-inhibitory effects of TGF-b1 and BMP 2 and 4, and 
had a decreased response to TGF-b1-mediated cell cycle arrest. Yin et al 
postulated that the induction of miR-155 plays a role in EBV-mediated B-cell 
activation and oncogenesis, partly by its effect on Smad5. miR-155 has been shown 
to inhibit BMP-mediated EBV reactivation by targeting several members of the 
TGF-b/BMP signalling pathway including Smad5. miR-155 also plays a role in 
reversing BMP-mediated cell growth inhibition in lung epithelial cells [169]. 
Through these studies, not only have links between miR-155 and a PAH-relevant 
pathway been established, but miR-155 overexpression has been shown to convey 
resistance to regulation of cell growth.  
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1.6.3 miR-155 and Inflammation 
 
Elevated levels of inflammatory cells and cytokines such as IL-6 have been 
identified in PAH patients, as previously discussed. Many links between miR-155 
and inflammation and immunity have been established. Increased BIC/miR-155 
expression is found in activated B and T lymphocytes, as well as activated 
macrophages and monocytes [165]. Elevated miR-155 levels have been identified 
in synovial fluid and tissue from patients with rheumatoid arthritis, a chronic 
inflammatory condition [172]. miR-155 is also upregulated in rheumatoid arthritis 
synovial macrophages and monocytes, and it promotes the production of pro-
inflammatory cytokines including IL-6 and TNF-a [173].  
 
1.6.4 miR-155 and HIF-1a 
 
A role for miR-155 in the cellular response to hypoxia has been identified [174]. 
HIF-1a is recognised as a master regulator of the cellular response to hypoxia. 
Hypoxic upregulation of miR-155 has been demonstrated in colonic epithelial cells 
and, based on miRNA target prediction algorithms, HIF-1a is predicted to be a 
target of miR-155. This is confirmed by the observation that exogenous over 
expression of miR-155 decreased HIF-1a levels and activity in these cells, and 
downregulation of endogenous miR-155 with an antimiR restored HIF-1a levels and 
activity. A negative feedback loop between miR-155 and HIF-1a therefore appears 
to exist in this model. 
 
1.6.5 miR-155 and eNOS 
 
Nitric oxide produced by PAECs is a potent pulmonary vasodilator and in PAH the 
NO-sGC-cGMP pathway is dysregulated. This is the basis for the treatment of PAH 
with PDE5 inhibitors and stimulators of sGC, as discussed earlier. NO is generated 
through the action of endothelial NO synthase (eNOS). eNOS has been proven to 
be a direct target of miR-155, and miR-155 overexpression has been shown to 
decrease the production of NO from endothelial cells in the systemic circulation, 
through its effect on eNOS [175]. Furthermore, inhibition if miR-155 resulted in 
 49 
increased eNOS expression and NO levels. Whether this effect translates to the 
pulmonary circulation has not been proven. 
 
1.6.6 Summary 
 
Many triggers, pathways and processes are involved in the pathogenesis of PAH 
and pulmonary vascular remodelling and, although it has not yet specifically been 
examined in the disease, miR-155 appears to influence some of these: 
 
• The TGF-b/BMP pathway is clearly important in PAH, not least because of 
the pre-eminence of BMPR2 mutations as the major genetic cause of the 
disease. miR-155 directly controls Smad5, one of the signalling 
intermediaries from this pathway, with an inverse correlation 
demonstrated.  
• Elevated levels of miR-155 are found in inflammatory conditions such as 
rheumatoid arthritis and it promotes the production of IL-6, which is 
upregulated in PH, along with other cytokines.  
• eNOS is downregulated by miR-155, reducing NO levels and increasing 
vascular tone.  
• Hypoxia upregulates miR-155, which in turn downregulates HIF-1a, 
suggesting the presence of a negative feedback loop and therefore 
impacting on the cellular response to hypoxia. 
 
If these findings were to directly translate to the pulmonary circulation and PAH, 
it would imply that miR-155 has a detrimental influence through its actions on 
Smad5, IL-6 and eNOS. However, miR-155 may suppress the HIF-1a-mediated 
effects of hypoxia, offering a protective effect against PAH. 
 
 
1.7 Aims and hypothesis 
 
There have been significant advances in the understanding of the pathobiology of 
PAH over the past three decades. This has resulted in the availability of disease 
specific treatments with subsequent improvements in quality of life, exercise 
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tolerance and survival. However, these treatments primarily target 
vasoconstriction in the pulmonary circulation, and not the pulmonary vascular 
remodelling that is a cardinal feature of PAH. 
 
MicroRNAs have complex and, at times, contradictory actions. Although they have 
often been explored as therapeutic agents, it is clear that they are also important 
tools in the investigation of disease pathobiology. As outlined, microRNA-155 has 
a number of potential links to PH pathobiology. 
 
The principal aim of this thesis is to explore how the manipulation of microRNA-
155 can be used as a tool to understand the pathways and mechanisms which lead 
to pulmonary vascular remodelling in PH. Ultimately this should contribute to the 
development of treatments which more effectively target this remodelling, as 
these are needed to further improve survival in patients.  
 
The hypothesis behind this work is that microRNA-155 is an important regulator of 
the signalling pathways and mechanisms behind pulmonary vascular remodelling. 
Manipulation of miR-155 levels will lead to increased understanding of the 
pathobiology of PH, and its downregulation may possibly convey a protective 
effect against vascular remodelling processes by restoring normal Smad5 signalling 
and reducing p38 MAPK activity. 
  
The main basis for this work is a miR-155 knockout mouse model. The aims are: 
1. To establish the in vitro effect of miR-155 knockout on mouse PAFs with 
regards remodelling processes, including cell migration and proliferation, 
and to establish whether p38 MAPK and Smad5 signalling may be involved 
in these remodelling processes 
2. To validate these in vitro findings by the use of a second model, which will 
explore whether they are replicated across species and by using a different 
technique for miR-155 downregulation, namely pharmacological 
knockdown in rat PAFs 
3. To assess the effects in vivo of miR-155 knockout on the development of 
PH in the chronic hypoxic mouse model, as evaluated by RVSP, RVH and 
vascular remodelling. 
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Chapter 2  
 
Materials and Methods 
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2.1 General equipment, reagents & solutions 
 
Plasticware for tissue culture was obtained from Greiner Labortechnick Ltd 
(Gloucestershire, UK) and Corning Life Sciences (New York, USA). All general 
chemicals were of analar grade. Details about the composition and source of 
specific reagents, solutions and antibodies are laid out in table 2-1. 
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Solution/Reagent/Antibody Source/Composition 
Serum Free Medium Dulbecco’s Modified Eagle’s Medium (DMEM)  
2mM L-glutamine 
Penicillin 100iu/ml 
Streptomycin 100µg/ml 
(Obtained from Sigma, UK or Invitrogen, UK) 
Cell Culture Medium As above, with either 10% or 20% Fetal Calf 
Serum (FCS) (Sigma, UK) 
Phosphate buffered saline 
(PBS) solution 
Dissolve 1 PBS tablet (Sigma, UK) in 200mls 
distilled water to obtain a 137mM NaCl, 2.7 
mM KCl and 10mM Phosphate buffer solution 
(pH 7.4 at 25°C) 
Trypsin Solution 100ml 0.5% Trypsin 10X (Fisher Scientific, UK) 
400ml PBS solution 
Cryopreservation Solution 1ml dimethylsulphoxide (DMSO) (Sigma, UK) 
9ml 10% culture medium 
[3H]-Thymidine (1mCi/ml) Amersham, UK 
Ethanol Sigma, UK 
Trichloroacetic acid 5% 4.1g trichloroacetic acid powder (Sigma, UK) 
500mls distilled water 
Sodium Hydroxide 0.3M 6g sodium hydroxide (Sigma, UK) 
500mls distilled water 
Ecoscint scintillation fluid National Diagnostics 
Trypan Blue Gibco, UK 
Radioimmunoprecipitation 
assay buffer (RIPA) 
ThermoFisher Scientific 
NuPAGE SDS 
buffers/reagents 
ThermoFisher Scientific 
PBS/T wash buffer 2 litres PBS solution 
4ml Tween-20 (ThermoFisher Scientific) 
Non-fat milk powder  Marvel (Premier Foods, UK) 
ECL solution reagents ThermoFisher Scientific 
Total p38 MAPK antibody Cell signaling 
Phosphorylated p38 MAPK 
antibody 
Cell signaling 
Phosphorylated Smad5 
antibody 
Abcam 
Anti-rabbit IgG HRP-linked 
secondary antibody 
Cell signaling 
RNaseZap ThermoFisher Scientific 
AntimiR-155  
(mmu-miR-155-5p) 
mirVana, Life Technologies 
Negative control antimiR #1 mirVana, Life Technologies 
Lipofectamine 2000 ThermoFisher Scientific 
Opti-MEM reduced serum 
medium 
Life Technologies 
 
Table 2-1 Details of specific reagents, antibodies and solutions used in vitro 
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2.2 In vitro methods 
 
2.2.1 Primary cell culture 
 
Adventitial fibroblasts used throughout these studies were obtained from primary 
culture by explant, using rat or mouse pulmonary arteries. A combination of 
freshly explanted cells, along with cells which had previously been stored in liquid 
nitrogen were used. This technique has been employed in the Scottish Pulmonary 
Vascular Unit laboratory for many years and is well established. 
 
To prevent contamination of cell lines, procedures involving the preparation or 
use of culture medium, or the preparation of drugs and reagents were conducted 
under sterile conditions using a clean Microflow laminar flow hood (figure 2-1) 
that was liberally sprayed with 70% ethanol before each use. Sterlisation of non-
sterile equipment and consumables was performed using a Prestige Medical Classic 
200 autoclave. Non-sterile reagents were filtered through a 0.2µm pore filter. 
 
 
Figure 2-1 Microflow laminar flow hood 
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Galaxy-R incubators (figure2-2) were supplied by Wolf Laboratories (York, UK). 
 
 
Figure 2-2 Galaxy-R incubator 
 
 
2.2.1.1 Adventitial fibroblast explant/culture 
 
The main pulmonary artery was dissected free from a heart & lung tissue block 
using a dissecting microscope (Zeiss STEMI SV11). Excess adherent tissue was 
removed, and a section of the artery was opened longitudinally into a flat sheet. 
Fibroblasts were isolated using the Freshney technique [176] with some 
modifications [92]. This has previously been shown to result in a culture of pure 
fibroblasts [177]. Briefly, the intima and media layers of the vessel wall were 
removed by gentle abrasion with a sterile razor blade, leaving behind just the 
adventitia. This was subsequently dissected into 5mm2 pieces that were 
transferred to a 25cm3 culture flask, placed on the base at regular intervals. To 
the flask was added 2mls of 20% culture medium. 
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The flask was then incubated at 37°C with 21% O2 and 5% CO2. Cells subsequently 
grew out from the tissue segments within a few days, and once a monolayer of 
cells had formed the tissue fragments were aspirated away. Cells were then lifted 
from the base of the flask using trypsin (see section 2.2.1.2) and resuspended in 
culture medium in a fresh 25cm3 flask. Cells were trypsinised again after a further 
seven days and subsequently grown in 75cm3 culture flasks. 
 
 
Figure 2-3 Typical appearances of rat PAFs 
 
 
2.2.1.2 Routine cell maintenance 
 
Cells were routinely grown in 75cm3 culture flasks containing 10ml of 10% culture 
medium. The flasks were kept in a Galaxy R incubator set at 37°C. Cells were 
visually inspected using a light microscope (Olympus CK2), and had the culture 
medium replaced regularly, every 2 to 3 days. The cells were grown until almost 
fully confluent before passage. 
 
To passage cells, the culture medium was aspirated and cells were washed twice 
with 2ml of trypsin solution for approximately 10 seconds per wash. After the 
second wash was removed, cells were incubated for 5 to 7 minutes until they were 
seen to be detaching from the flask surface. This was aided further by gentle 
agitation, before 10ml of 10% culture medium was added to inactivate the trypsin 
and to resuspend the cells. A fraction of this cell suspension was then aliquoted 
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into a fresh 75cm3 culture flask containing suffient new 10% culture medium so 
that the total volume in the new flask was 10mls. The remainder of the cell 
suspension could be divided in 6, 12 or 24 well culture plates as required. All cells 
used for experiments were between passage 2 and 6. 
 
2.2.1.3 Cell Storage 
 
Fully confluent cells at an early passage were trypsinised and resuspended in 10ml 
of 10% culture medium. The suspension was then centrifuged for 10 minutes at 
3000rpm. The resulting cell pellet was then resuspended in 1ml of 
cryopreservative solution and transferred to a cryotube. The cells were 
subsequently cooled at +4°C and -20°C for 1 hour each, before being placed in 
the -80°C freezer overnight. The cryotubes were then transferred to liquid 
nitrogen for longer term storage. 
 
When required, cryotubes of frozen cells were rapidly thawed at 37°C in a water 
bath.  The thawed contents of the cryotube were resuspended in 9mls of 10% 
culture medium and transferred to a cell culture flask. Once the cells had adhered 
to the flask surface, the culture medium was exchanged to minimise exposure of 
the defrosted cells to dimethylsulphoxide. 
 
2.2.2 Acute hypoxia 
 
Maintenance of cells in the Galaxy R incubator allows the control of oxygen 
concentration between 0% and 21%, through the supplementation of the 
atmosphere with nitrogen. When hypoxic conditions were required, a Pneuchange 
automatic gas cyclinder change-over unit (NTC, Woulton, Liverpool, UK), was used 
to supply fresh nitrogen from cylinders on demand, until the desired degree of 
hypoxia was achieved. The incubator is also connected to a CO2 cylinder which 
supplements the chamber to maintain CO2 levels at 5%. 
 
An environment of 5% O2 has previously been established by the laboratory to 
maintain a cell pO2 of 35mmHg with a stable physiological pH. Experimental 
controls were maintained in a second incubator set at normal atmospheric oxygen 
levels (21%).  
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2.2.3 Assessment of cell proliferation 
 
2.2.3.1 [3H]-Thymidine proliferation assay 
 
Use of this technique allows determination of cellular proliferation by measuring 
the incorporation of  [3H]-Thymidine into DNA during cell division. 
 
PAFs were seeded at a density of 5x103 cells per well into 24-well plates. Each 
well contained 500µl of 10% culture medium, and the plates were incubated until 
cells reached 60% confluency. Culture medium was then replaced with 500µl 
serum-free medium for 24 hours to quiesce the cells. The appropriate reagents or 
conditions under investigation were then applied, and plates were incubated for 
a further 24 hours in hypoxia or normal atmospheric conditions, as required. 
 
A dilute solution of [3H]-Thymidine was prepared by adding 10µl of the stock 
solution (1mCi/ml) to 2.5ml of serum-free culture medium. For the final 4 hours 
of an experiment, 25µl of the dilute [3H]-Thymidine solution was added to each 
well. 
 
At the end of the experiment, the reaction was halted by washing each well twice 
with 500µl of ice-cold phosphate-buffered saline. Precipitation of proteins was 
achieved by washing 3 times with 5% trichloroacetic acid (TCA, 500µl/well/wash). 
Washing each well twice with 500µl of 100% ethanol resulted in lipid fractions 
being solubilised. The resultant material was then dissolved in 0.3M sodium 
hydroxide, 200µl per well, for 30mins. Each well’s contents were then transferred 
to a 1ml eppendorf tube, and 1.2ml of Ecoscint scintillation solution was added. 
Each eppendorf was gently agitated to mix the contents and allowed to settle 
overnight in darkness. Radioactivity was then quantified using a Wallac 1409 
scintillation counter, and expressed as either degradations or counts per minute 
(DPM or CPM, respectively). 
 
2.2.3.2 Cell counting & trypan blue staining 
 
Cells seeded into approriate well plates were used for experiments as desired. 
Once these were complete, the cells were treated briefly twice with 400µl of 
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trypsin solution before being resuspended in 1ml PBS solution.  100µl of the cell 
suspension was added to 100µl of 0.4% trypan blue solution, and 20µl of the 
resulting solution was transferred to a Neubauer Haemocytometer. Cells which 
stain blue are non-viable, and by counting the total cells and the non-viable cells 
in 4 of the squares marked out on the haemocytometer’s grid (using a light 
microscope at low power), the percentage of viable cells could be calculated.  
 
To ascertain the total number of cells in the initial solution, the following equation 
was used: 
 
2.2.4 Assessment of cell migration 
 
Cellular migration was assessed using a scratch wound assay. Six-well plates of 
fully confluent fibroblasts were serum starved for 24 hours before vertical 
scratches were drawn through the confluent cell monolayer using a p200 pipette 
tip. Cells were washed with serum-free medium to remove any debris before fresh 
serum-free medium was added to each well. A photograph of the scratch in the 
cell monolayer was then taken, using a digital SLR camera. Prior to use, the well 
plates had been lightly pre-scored on the underside to aid orientation when 
photographs were being taken. 
 
The 6-well plates were incubated for a further 24 hours after experimental 
conditions were applied, before being re-photographed at the same location.  
Using the photographs, quantitative assessment of migration was made by 
calculating the percentage closure over 24 hours. The width of each scratch was 
measured 4 times, at regular intervals along its length. Percentage closure of the 
scratch was calculated as:  
 
% closure = [width at 24 hours / width at 0 hours] x100 
 
 
 
No. of cells in original solution =  2x  [Total no. of cells in 4 squares/4]  x10000 
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2.2.5 Detection & analysis of proteins 
 
2.2.5.1 Preparation of cell samples for protein analysis 
 
Cell were grown to 90% confluency in 6-well plates, before being quiesced using 
serum-free medium for 24 hours. The conditions under investigation were then 
applied. Once the experiment was complete, culture plates were placed on ice 
and the culture medium removed. Each well was washed twice with 500µl of ice-
cold PBS solution. Cell lysis was achieved by the addition to each well of 50µl of 
radioimmunoprecipitation assay (RIPA) buffer for 10 minutes.  This was augmented 
by mechanical disruption, using a cell scraper. The resulting solution was 
aspirated and stored in a 1ml eppendorf tube at -80°C until needed. 
 
2.2.5.2 SDS-PAGE gel electrophoresis 
 
Protein samples were analysed by sodium dodecyl sulfate polyacramide gel 
electrophoresis (SDS-PAGE). An appropriate quantity of the cell lysate, prepared 
as above, was added to SDS sample buffer and reducing agent. The samples were 
then incubated in a 70°C water bath for 5 minutes to denature proteins and 
disrupt disulphide bonds.  
 
The samples were then loaded into individual lanes of  precast 10% gel cassettes 
(Life Technologies, UK), using loading tips. The first lane of each cassette was 
loaded with See-Blue prestained molecular weight marker, to allow protein sizes 
to be determined. The SDS-PAGE cassettes were then assembled into a XCell-II 
electrophoresis/blotting cube. The two compartments of the cube were 
subsequently filled with SDS Running Buffer and the gels were then subjected to 
electrical  current. A voltage of 150V was applied for 100 minutes, whilst the cube 
was cooled by surounding its base with ice (figure 2-4). 
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Figure 2-4  XCell II electrophoresis/blotting cube 
 
 
2.2.5.3 Transfer to nitrocellulose membrane 
 
Once electrophoresis was complete, the apparatus was disassembled and the gels 
carefully removed from their plastic cassettes. The gels were then layered into a 
transfer module, with a nitrocellulose membrane (which had been pre-activated 
with methanol) positioned between the gel and the cathode. The transfer module 
was then inserted into the blotting cube, and Transfer Buffer was added. A voltage 
of 30V was applied for 60mins, resulting in the transfer of negatively charged 
proteins onto the membrane. 
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2.2.5.4 Immunoblotting 
 
The nitrocellulose blots were washed in PBS/T wash buffer and blocked for non-
specific binding for 1 hour on a Gyro-Rocker platform in PBS/T supplemented with 
10% non-fat milk (w/v), at room temperature. Blots were then incubated for 1 
hour in PBS/T with 5% non-fat milk (w/v) containing the primary antibody at an 
appropriate dilution. The blots were rinsed and washed 4 times with PBS/T and 
then incubated for 60 minutes with the secondary antibody, usually anti-rabbit 
IgG conjugated to Horseradish peroxidase (HRP), in PBS/T with 5% non-fat milk at 
a concentraion of 1:2000. The blots were then washed as before. 
 
2.2.5.5 Antibody detection 
 
Following completion of washing procedures, proteins were detected using a 
method of enhanced chemilumenescence (ECL). Briefly, light emission from the 
action of HRP on its substrate within the ECL solution is detected on x-ray film as 
bands representing the proteins that have bound to the HRP-linked antibody. Blots 
were incubated in ECL solution for 30 seconds and then sandwiched between 
acetate film, ensuring all air bubbles were dispelled. Blots were then placed in a 
cassette with x-ray film for between 1 and 10 minutes, before the x-ray film was 
fed through a KODAK M35-M X-OMAT processor.  
 
2.2.5.6 Re-probing membranes 
 
If it was desirable for a nitrocellulose membrane to be probed for different 
proteins, primary and secondary antibodies were stripped from the membrane by 
incubating it in Stripping Buffer (Restore, ThermoFisher Scientific) for 30mins. The 
membranes were then rinsed with PBS/T, before the immunoblotting procedure 
was repeated with a different primary antibody. 
 
2.2.5.7 Densitometry 
 
Each protein band from the blot was then analysed by densitometry using Image 
J software (National Institutes of Health, USA). The density of the band under 
examination could be quantified as a ratio, relative to a control protein band.  
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2.2.6 Knockdown of miR-155 by liposomal transfection 
 
Transient knockdown of miR-155 was achieved through liposomal transfection of 
antimiR-155. RNase contamination on surfaces within the laminar flow hood was 
minimised through liberal spraying with RNaseZap® decontamination solution. Rat 
PAFs were cultured using antibiotic-free DMEM containing 10% serum, in 6-well or 
24-well plates, as necessary for the particular experiment, until they were 60-80% 
confluent.  
 
AntimiR-155 and the negative control antimiR (both from mirVana, Life 
Technologies) were reconstituted with nuclease-free water per instructions 
supplied with the product, resulting in a 50µM (50pmol/µL) working stock solution. 
The transfection reagent used to introduce the antimiR into the cell was 
Lipofectamine 2000.  
 
Lipofectamine 2000-antimiR complexes were prepared at a ratio of 1:1 in Opti-
MEM reduced serum media. To achieve this, two separate tubes were prepared 
for each transfection. The first tube contained antimiR & Opti-MEM, mixed gently 
by pipetting, and the second tube contained Lipofectamine and Opti-MEM, mixed 
gently. Both tubes were incubated for five minutes before the contents were 
combined and incubated for a further 20 minutes.  
 
Once the Lipofectamine 2000-antimiR complexes were prepared, the culture 
medium in each well was replaced with an appropriate quantity of fresh Opti-
MEM. The Lipofectamine-antimiR complexes were then added to the cells, such 
that the final concentration of antimiR was 50nM. Cells were returned to the 
incubator, and 24 hours later the Opti-MEM was replaced with DMEM containing 
the desired amount of serum. Proliferation assays, protein analysis or migration 
studies could then be undertaken as above. 
 
 
 
 
 
 
 64 
2.3 In vivo methods 
 
MicroRNA-155 knockout (KO) mice and age-matched wild type (WT) controls were 
used throughout for in vivo experiments. These were kindly donated by Dr Charles 
McSharry and Dr Mariola Kurowska-Stolarska (Institute of Infection, Immunity and 
Inflammation, University of Glasgow). Mice were kept at the University of Glasgow 
animal house, in pathogen-free conditions managed by the biological services staff 
at the University. All animals were kept in strict accordance with guidelines set 
out by the United Kingdom Home Office Animal (Scientific Procedures) Act 1986. 
All procedures were carried out under project licence number PL60-4404, held by 
Professor M MacLean, Institute of Cardiovascular and Medical Sciences, University 
of Glasgow. 
 
2.3.1 Chronic hypoxic animal model 
 
2.3.1.1 Hypobaric chamber design 
 
A hypobaric chamber was used to create a hypoxic environment. Transparent high 
resistance plexiglass was used to construct the chamber, which comprises of two 
separate compartments. Use of a vacuum pump lowers the pressure inside the 
chamber to a final pressure of 550mbar, equivalent to 10% O2. A constant flow of 
air through the chamber prevented the accumulation of moisture and CO2. The 
chamber was housed in a dedicated room, allowing the regulation of temperature 
(at 21°C) and humidity, and a regular 12-hour on/12-hour off light cycle.  
 
2.3.1.2 Induction of PH & animal maintenance 
 
Up to 12 animals in 2 cages were placed in the chamber at any one time. Pressure 
was gradually reduced to 550mbar over 48 hours to allow acclimatisation. Animals 
were subjected to this hypoxic environment for 14 days to allow PH to develop. 
Frequent checks were made throughout the day to ensure the animals were not 
distressed and the equipment was functioning optimally. When care for the 
animals was needed, the chamber was brought back to atmospheric pressure over 
1 hour.  Cleaning and replenishment of food and water was carried out and the 
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pressure was re-established over a further 1 hour. Control (“normoxic”) mice were 
housed in the same room at normal atmospheric pressure, equivalent to 21% O2. 
 
2.3.2 Assessment of pulmonary hypertension 
 
2.3.2.1 Anaesthesia 
 
Administration of 3% Isoflurane (Abbott Laboratories, Berkshire, UK) in an 
anaesthetic box was used to induce anaesthesia in the mice. This was 
supplemented with oxygen 0.5L/min. The mice were then immediately weighed 
and transferred to a facemask which continuously delivered 1.5% isoflurane, 
supplemented with oxygen. The absence of hind-limb or tail reflexes was used to 
confirm that the required depth of anaesthesia had been achieved. This was 
monitored throughout the procedure, along with heart rate and respiratory rate, 
to ensure anaesthesia was neither too deep nor too shallow. At the end of the 
procedure, the mice were sacrificed using a terminal dose of anaesthesia. 
 
2.3.2.2 Haemodynamics 
 
Right ventricular pressure was measured by cannulating the right internal jugular 
vein with A Millar Mikro-Tip® PVR-1030 pressure-volume catheter, which was then 
slowly advanced into the right ventricle until a typical RV pressure trace with even 
oscillations was obtained. Recordings were made using the PowerLab data 
acquisition system (AD Instruments, Oxford, UK) and analysed using LabChart v7 
software. Although not performed for this work, systemic pressures should be 
measured as a part of future research. This would then clarify whether any 
haemodynamic effect of miR-155 down-regulation was specific to the pulmonary 
circulation. 
 
 
Figure 2-5 Typical right ventricular systolic pressure trace 
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2.3.2.3 Right ventricular hypertrophy 
 
RVH was assessed using Fulton’s Index [178]. The right ventricular free wall (“RV”) 
was separated from the left ventricle and septum (”LV+S”) using a dissecting 
microscope.  The LV was subsequently opened flat, and all tissue was blotted dry 
and weighed. The ratio of the mass of the RV to LV+S was used to assess the degree 
of RV hypertrophy. 
 
 
Figure 2-6 Right ventricle (right) dissected from left ventricle and septum 
 
 
2.3.2.4 Pulmonary vascular remodelling 
 
Solutions and reagents used for histology are summarised in table 2-2. 
 
Solution/reagent Composition/source 
Dulbecco’s PBS Sigma, UK 
10% neutral buffered formalin Sigma, UK 
Histoclear ThermoFisher Scientific 
0.5% potassium permanganate 1g KMnO4 in 200ml distilled water 
1% oxalic acid 2g oxalic acid in 200ml distilled water 
Miller’s elastic stain Sigma, UK 
Picro-sirius red Sigma, UK 
Acidified water 5ml Glacial acetic acid in 1L distilled water 
 
Table 2-2 Details of specific reagents and solutions used for histology 
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Immediately following sacrifice, the lungs were gently flushed with Dulbecco’s 
phosphate buffered saline solution. They were then gently inflated with 10% 
neutral buffered formalin solution (NBF), before being placed in NBF solution at 
least overnight. After fixation in formalin, the tissue was dehydrated through a 
water-Histoclear gradient and subsequently embedded in paraffin using a Citadel 
100 tissue processor (ThermoScientific, UK). Tissue blocks were then stored in a -
20°C freezer to solidify the paraffin. The tissue blocks were then sliced into 5µm 
sections using a microtome (Leica RM2125, Leica Microsystems, Milton Keynes, UK) 
and placed in a 37°C water bath to gently melt the paraffin. The sections were 
then transferred onto histology slides (VWR) and left to dry.  
 
The slides were then treated with Histoclear and rehydrated through an ethanol-
water gradient, before immersion in 0.5% potassium permanganate solution, 
followed by decolourisation using 1% oxalic acid. The sections were then stained 
with Miller’s elastic stain and counter-stained with picro-sirius red. The sections 
were washed in acidified water, then rapidly dehydrated with ethanol before final 
washes with Histoclear. The slides were then mounted, ready for analysis.  
 
Analysis was performed in a blinded fashion. Peripheral pulmonary vessels smaller 
than 80µm external diameter that were not in proximity to an airway were 
examined. A vessel was considered to be remodelled if greater than 50% of the 
circumference of the vessel had a double elastic lamina, which appeared black 
after staining. Remodelling was expressed as a percentage: 
 
% pulmonary vascular remodelling = [remodelled vessels/total vessels] x100 
 
 
2.4 Statistical analysis of data 
 
For normally distributed values, data was reported as mean +/- SEM, and Students 
t-test was used. For multiple comparisons of means across different groups, one-
way or two-way analysis of variance (ANOVA) was used as appropriate, with 
Bonferonni post-hoc analysis (Prism v7, GraphPad, California). In animal 
experiments, n = number of animals per condition.  p<0.05 was accepted as 
significant throughout. 
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Chapter 3 
  
Knockout of microRNA-155 influences remodelling 
processes and signalling pathways in mouse 
pulmonary artery fibroblasts 
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3.1 Introduction 
  
As described in the general introduction chapter, changes in all three layers of 
the vessel wall contribute to the pulmonary vascular remodelling typically seen in 
pulmonary hypertension [18].  
 
Endothelial cells are the predominant constituent of the intimal layer. In response 
to stimuli such as inflammation and shear stress they undergo proliferation, 
contributing to neointimal thickening and the formation of plexiform lesions, 
resulting in vessel remodelling [41, 42]. The intima is also directly influenced by 
various vasoactive mediators such as nitric oxide and endothelin. It is therefore 
important when it comes to the mechanism of action of most of the current 
treatments for PAH, which depend on these mediators [41]. Further vascular 
remodelling results from hypertrophy and muscularisation of the medial layer, at 
least in part due to the imbalance between proliferation and apoptosis of 
pulmonary artery smooth muscle cells seen in PH [35]. 
 
Adventitial fibroblasts are key orchestrators of the cellular response to hypoxia 
and the vascular remodelling seen in hypoxic pulmonary hypertension. In the 
adventitia, a combination of increased extracellular matrix deposition along with 
fibroblast proliferation leads to thickening of the vessel wall.  Additionally, 
activated fibroblasts undergo transformation to myofibroblasts, the subsequent 
migration of which leads to the muscularisation of distal vessels which were 
previously non-muscularised [29, 34]. These processes indicate that the fibroblast 
is a valuable target for research into causative mechanisms and potential 
therapeutic interventions in hypoxic pulmonary hypertension. 
 
Utilisation of the hypoxic model of PH and its effect on PAFs for the work in this 
thesis is justified by previous findings from both within the SPVU laboratory, where 
it is a well-established model, and from others. These findings include the 
proliferative response of PAFs to acute hypoxia [92], which has been shown to be 
selective for the pulmonary circulation (as it is not seen in fibroblasts from the 
systemic circulation) and to be preserved across animal species [87, 90]. 
Furthermore, the proliferative and signalling mechanisms activated in acutely 
hypoxic PAFs mirror those seen in PAFs from chronic hypoxic animals. p38 MAP 
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kinase, a stress-responsive protein, has been shown to play an essential role in 
the interplay between hypoxia and PAFs [89-91]. Upregulation of p38 MAPK has 
been shown in PAFs in response to hypoxia, and inhibition of p38 MAPK preventing 
or reversing the hyperproliferative effect of hypoxia on PAFs. The p38 MAPK 
pathway has also been shown to be activated in PASMCs with BMPR2 mutations. 
These mutations are a key genetic cause of PAH, and they result in ineffective 
Smad signalling through the TGF-β/BMP pathway [74]. 
 
MicroRNAs are non-coding strands of RNA which act as post-transcriptional 
regulators of gene expression, through the repression or degradation of the 
messenger RNA to which they bind [131]. Many thousands of microRNAs have been 
identified to date. Their actions are complex, as a single miRNA is capable of 
regulating many genes and a single gene may be regulated by multiple miRNAs 
[137]. Whilst many microRNAs are widely conserved across species, the extent of 
their expression, and therefore their effect, can vary between species and also 
between different stages of development within a species [147]. Despite this, 
their influence on gene expression makes them attractive tools for studying 
signalling pathways and disease aetiology. This can be done by manipulation of 
microRNA levels either pharmacologically or through the use of transgenic 
animals. Furthermore, pharmacological manipulation of microRNAs has also been 
explored as a therapeutic intervention, including in a human clinical trial on the 
treatment of Hepatitis C [149]. However, given their complex roles and 
interactions, and the potential for “off-target” effects it is unclear whether 
microRNA manipulation could become an established treatment strategy. 
 
Many of the causative stimuli of PH can modify microRNA expression in vascular 
cells. This dysregulation impacts on signalling pathways and influences many of 
cellular processes behind vascular remodelling, including proliferation, apoptosis 
and migration [132]. Various microRNAs have been studied in PH, although the 
results are often complex and at times contradictory. MicroRNA-21 has been 
extensively studied. In vitro, upregulation of miR-21 in response to hypoxia is seen 
in human PAECs [155] and human PASMCs [156]. Upregulation is also seen in lung 
tissue from chronically hypoxic mice [157], as well as in the SU5416/hypoxia 
mouse model and in PAH patients [155]. Accordingly, downregulation of miR-21 
results in reduced hypoxic proliferation and migration of human PASMCs [156], 
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and can prevent/reverse PH in mice exposed to chronic hypoxia [157]. This 
suggests that miR-21 contributes to the development of PH. However, evidence 
contradictory to this includes the finding that miR-21 is downregulated in the 
monocrotaline rat model [154]. Other noteworthy microRNAs studied in PH are 
outlined in the general introduction chapter. 
 
MicroRNA-155 plays a role in numerous biological processes and diseases including 
inflammation, immunity, haematopoiesis and malignancy [165]. It has also been 
demonstrated to target many genes with links to pathways that are important in 
the pathogenesis of PH. Smad5, an intermediary in the TGF-β/BMP signalling 
family, has been shown to be a direct target of miR-155 [167]. An inverse 
correlation between Smad5 and miR-155 has been demonstrated in diffuse large 
B-cell lymphoma cells lines, with ectopic overexpression of miR-155 resulting in 
downregulation of Smad5 and miR-155 inhibition resulting in elevated Smad5 
levels. More aggressive forms of DLBCL have been shown to overexpress miR-155, 
with such cells showing resistance to TGF-b1-mediated cell cycle arrest, and a 
decreased response to the growth-inhibitory effects of BMP 2 and 4 [170, 171]. 
This suggests miR-155 overexpression is linked to dysregulated cell growth. 
 
The cellular response to hypoxia is also under the influence of miR-155, through 
links to HIF-1a, a master regulator of this response.  A negative feedback loop 
between miR-155 and HIF-1a has been demonstrated in colonic epithelial cells 
where exogenous miR-155 overexpression decreases HIF-1a levels and activity, 
and downregulation via antimiR-155 restored HIF-1a activity [174]. Inflammation 
plays an important role in PAH pathogenesis, and microRNA-155 has been linked 
to inflammatory diseases including rheumatoid arthritis [172], with evidence that 
it promotes production of IL-6 and other cytokines in the disease [173]. Finally, in 
the systemic circulation miR-155 overexpression has been demonstrated to 
decrease endothelial production of nitric oxide, a potent vasodilator, through its 
control of endothelial NO synthase (eNOS) [175]. This suggests that there could be 
a role for miR-155 influencing vascular tone in the pulmonary circulation, although 
this has not been proven. 
 
The aim of this thesis is to show that manipulation of microRNA-155 is a useful 
tool to enhance understanding of the mechanisms and signalling pathways behind 
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pulmonary vascular remodelling in PH. This greater understanding should 
contribute to the development of new treatments which more effectively target 
this remodelling and improve patient survival. Within this chapter, the aim is to 
establish the in vitro effect of miR-155 knockout on mouse PAFs with regards 
remodelling processes, including cell migration and proliferation, and to establish 
whether p38 MAPK and Smad5 signalling may be involved in these remodelling 
processes.  
 
As miR-155 has been shown to promote dysregulated cell growth and 
inflammation, and to affect the action of HIF-1a, I hypothesised that miR-155 
downregulation would counteract hypoxia-driven proliferation and migration of 
PAFs. Upregulation of Smad5 was also predicted, given the previously 
demonstrated inverse correlation between miR-155 expression and Smad5 levels, 
which could be a possible pathway by which manipulating miR-155 would lead to 
an effect on migration and proliferation. Given the link between p38 MAPK and 
BMPR2 mutations, and therefore the TGF-β/BMP signalling pathway, p38 MAPK 
was also predicted to be another possible pathway through which miR-155 may 
act, with reduced p38MAPK activity predicted when miR-155 was downregulated. 
Overall this led to a hypothesis that miR-155 knockout would be protective against 
PH. The experiments in this chapter were conceived to clarify these hypotheses. 
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3.2 Relevant methods 
 
Detailed methods pertaining to proliferation and migration assays, as well as 
protein detection and quantification are outlined in Chapter 2. Briefly, the rate 
of incorporation of [3H]-Thymidine by PAFs under specific conditions was used as 
an indirect measure of proliferation. Migration was measured by the degree of 
closure of a scratch in a monolayer of PAFs when experimental conditions were 
applied.  
 
The Western blot technique was employed for protein detection and 
quantification. The primary antibodies used for immunoblotting, along with their 
specific dilutions were as follows: 
• Phosphorylated p38 MAPK (1:500) 
• Total p38 MAPK (1:500) 
• Phosphorylated Smad5 (1:1000) 
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3.3 Results 
 
3.3.1 MicroRNA-155 knockout ameliorates the proliferation of PAFs 
in acute hypoxia 
 
To examine the effect that miR-155 knockout in mice would have on hypoxia-
driven PAF proliferation, [3H]-Thymidine assays were performed, comparing wild 
type MPAFs with KO MPAFs. The results are displayed in figure 3-1. 
 
When cultured with increasing doses of serum in normoxic conditions, a 
progressive increase in proliferation of wild type mouse PAFs was noted, as 
indicated by higher radioactivity counts. This effect was augmented when the WT 
MPAFs were exposed to hypoxia, with statistially significant differences first noted 
at 5% serum. The additional proliferative response was masked at the highest 
serum dose (10%), likely due to cellular contact inhibiting further proliferation. 
 
When the proliferation assay was repeated with PAFs from miR-155 KO mice, the 
additional hyperproliferative response of the PAFs to hypoxia was altered. Whilst 
the response to serum in a dose-dependent fashion was maintained, the additional 
effect of hypoxia on DNA synthesis was not seen. This indicates that the 
proliferative response to hypoxia was abrogated in the knockout PAFs. 
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Figure 3-1 The hypoxia-enhanced proliferative response of Wild Type MPAFs is not seen in 
miR-155 knockout MPAFs. 
WT MPAFs were cultured in normoxic conditions with the addition of [3H]-Thymidine for the final 
4 hours. The effect of stimulation with increasing doses of serum was observed. Increased 
proliferation with higher doses of serum was noted, as indicated by increased incorporation of 
[3H]-Thymidine with radioactivity measured as CPM. When repeated with WT MPAFs in hypoxia, a 
trend towards an additional proliferative effect was seen, above that of the serum dose alone. 
This reached statistical significance at 5% serum, although the signal was lost at 10% serum, 
possibly due to contact inhibition. When repeated with miR-155 knockout MPAFs, the dose-
dependent proliferative response to serum was maintained. However, KO MPAFs did not 
demonstrate any additional response to hypoxia. Four experiments per condition were conducted, 
with values expressed as mean +/- SEM. Results were analysed using 2-way ANOVA with Bonferroni 
post-hoc analysis. ****p<0.0001. 
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3.3.2 Hypoxia-induced migration of PAFs is reduced in microRNA-
155 knockout 
 
The scratch assay was utilised to evaluate cell migration. A vertical scratch was 
made through a cellular monolayer of both WT and KO MPAFs and, after further 
incubation in either normoxic or hypoxic conditions, the degree of closure of the 
scratch during this incubation was assessed.  
 
After 24 hours in normoxic conditions, the scratch created in the WT MPAFs had 
narrowed only marginally, to 96% of its original width. However, after 24 hours in 
hypoxia the WT PAFs had migrated to such an extent that the scratch had closed 
completely, p<0.01 (figure 3-2A).  
 
The knockout MPAFs however did not demonstrate this migratory response to 
hypoxia. After 24 hours, there was no statistically significant difference between 
the change of the hypoxic and normoxic KO MPAF scratches (figure 3-2B).  
 
The width of each scratch was measured at 4 points and the results were displayed 
graphically (figure 3-2C). 
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Figure 3-2 Migration of MPAFs in response to hypoxia is diminished in miR-155 knockout 
compared with wild type. 
(A) Wild type MPAFs were cultured until there was a fully confluent monolayer of cells. A scratch 
was then drawn down through the layer of cells and photographed. Additional incubation in hypoxic 
or normoxic conditions for another 24 hours was carried out. After this time, the width of the 
remaining scratch was compared to the scratch at baseline i.e. 0h. Four measurements were taken 
at equal distances along the length of each scratch. In normoxic conditions, there is negligible 
change in the size of the scratch. However, in hypoxia, migration of the WT MPAFs results in 
closure of the scratch after 24h. (B) The scratch assay was repeated using miR-155 KO MPAFs. In 
contrast to the WT MPAFs, hypoxia does not induce a migratory response after 24h, with no 
reduction in the width of the scratch. (C) Graphical representation of the change in scratch size 
after 24h in each condition, expressed as a percentage of the original scratch size. Data presented 
as mean +/- SEM, analysed by 2-way ANOVA with Bonferroni post-hoc analysis, **p<0.01, 
***p<0.001. 
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3.3.3 Knockout of microRNA-155 leads to a greater expression of 
Smad5 in hypoxia 
 
The literature suggests that miR-155 controls expression of Smad5, with an inverse 
correlation demonstrated between the two. The combined effects of miR-155 KO 
and hypoxia on Smad5 levels in MPAFs were investigated by culturing WT and KO 
cells with increasing doses of serum in either normoxic or hypoxic conditions. 
Immunoblotting for phosphorylated Smad5 was performed, with total p38 MAPK 
used as a control. Protein levels were then quantified by densitometry. 
 
Figure 3-3 displays the results. In MPAFs under normoxic conditions, the inverse 
correlation between miR-155 and Smad5 was not seen. In fact, there was more of 
a signal to suggest that Smad5 levels were lower in the KO cells in normoxia. 
 
However, under hypoxia conditions this inverse relationship was demonstrated.  
Whilst there was some increase in Smad5 levels in the WT MPAFs in hypoxia, this 
was significantly enhanced in the KO MPAFs, p<0.0001. This was seen in all of the 
concentrations of serum used. 
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Figure 3-3 Phosphorylated Smad5 levels are upregulated in hypoxic conditions, especially in 
miR-155 knockout MPAFs. 
(A) PAFs were isolated from both wild type and knockout mice and stimulated with increasing 
doses of serum and cultured for 24 hours in either normoxic or hypoxic conditions. Cell lysates 
were immunoblotted for phosphorylated Smad5 and total p38 MAPK. In normoxic conditions, the 
inverse correlation between miR-155 and Smad5 levels was not seen. However in hypoxia, whilst 
both cell types show increased phosphorylated Smad5 levels, this is especially the case with the 
KO MPAFs. Molecular weights: phosphorylated Smad5 52kDa, total p38 MAPK 43kDa. (B) Results 
quantified, using densitometry, as density relative to total p38 MAPK. Data presented as mean +/- 
SEM. Analysed by 2-way ANOVA with Bonferroni post-hoc analysis, ****p<0.0001 
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3.3.4 Hypoxia-induced phosphorylation of p38 MAPK in PAFs is lost 
in microRNA-155 knockout 
 
Activation of the p38 MAPK signalling pathway is seen when PAFs hyperproliferate 
in response to hypoxia. It was hypothesised that the lack of hypoxia-driven 
proliferation in KO MPAFs demonstrated earlier in this chapter may be due to miR-
155 downregulation preventing hypoxic activation of p38 MAPK. To investigate, 
WT and KO MPAFs were cultured with increasing doses of serum in hypoxia or 
normoxia. Immunoblotting for phosphorylated and total p38 MAPK was performed.  
 
Figure 3-4 shows these immunoblots along with a graphical quantification of 
phosphorylated p38 MAPK. WT MPAFs cultured in hypoxia demonstrate enhanced 
p38 MAPK phosphorylation compared with the WT cells under normoxic conditions. 
This is the expected result, based on previous work.  
 
When this was repeated using the miR-155 KO MPAFs, the ability of hypoxia to 
activate the p38 MAPK signalling pathway was lost. A signal was also detected 
which suggested that even without hypoxic stimulation (i.e. under normoxic 
conditions) the WT MPAFs showed greater levels of phosphorylated p38 MAPK than 
the KO MPAFs. 
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Figure 3-4 The effect of hypoxia on the phosphorylation of p38 MAPK is abrogated in miR-155 
knockout MPAFs compared with wild type MPAFs. 
(A) Wild type and knockout MPAFs were stimulated with increasing quantities of serum. They were 
then cultured in normoxia or hypoxia for 24 hours. Cell lysates were subsequently immunoblotted 
for total p38 MAPK and phosphorylated p38 MAPK. When cultured in hypoxia, the WT MPAFs showed 
the expected response, a rise in phosphorylated p38 MAPK levels. However, this response to 
hypoxia was not seen in the KO MPAFs. Molecular weights: both 43kDa. (B) Results quantified, 
using densitometry, as density relative to total p38 MAPK. Data expressed as mean +/- SEM, 
Analysed by 2-way ANOVA with Bonferroni post-hoc analysis, ****p<0.0001. 
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3.4 Summary 
 
The results from this chapter have shown that miR-155 knockout can be used to 
understand PH pathobiology through the mechanisms and pathways which 
contribute to pulmonary vascular remodelling. 
 
Fibroblasts play a key early role in the cellular response to hypoxia and subsequent 
vascular remodelling. The proliferation of PAFs in response to hypoxia leads to 
adventitial thickening, which contributes to PH [22, 23]. Results from this chapter 
have shown the expected proliferative response of WT MPAFs to hypoxia. 
However, this response to hypoxia is clearly lost in miR-155 KO MPAFs. These 
results are in-keeping with the predicted outcome, based on the original 
hypothesis that miR-155 KO would be protective against PH. 
 
The transformation of PAFs into myofibroblasts and their migration from the 
adventitia leads to muscularisation of distal vessels and further drives pulmonary 
vascular remodelling [28, 29]. However, knockout of miR-155 in this mouse model 
prevented the migration of PAFs in response to hypoxia, with a clear persistence 
of the scratch in the migration assay. This therefore appeared to be a successful 
result as it is also in-keeping with the original hypothesis. 
  
In order to elucidate possible pathways through which miR-155 KO may be exerting 
these effects on PAFs, a relationship with Smad5 was investigated. Smad5 is a key 
component of the TGF-b/BMP signalling pathway, which is important in PH. Smad5 
is also an established target of miR-155, and an inverse correlation between the 
two has been illustrated previously [167]. Under basal normoxic conditions, the 
KO MPAFs showed generally lower levels of phosphorylated Smad5, compared with 
their wild type counterparts. When repeated in hypoxia, the result was an 
increase in the levels of phosphorylated Smad5 in both cell types. This was 
however to a much greater extent in the knockout PAFs. This inverse relationship 
was therefore only seen under hypoxic conditions. 
 
The Smad5 experiments appeared to be generally successful in so far as they 
confirmed a link between miR-155 and Smad5, at least in hypoxia. Hypoxia itself 
may lead to an increase in Smad5 phosphorylation, and hence the increased levels 
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in the WT cells in hypoxia. However, it’s clear that miR-155 KO enhances this 
effect. There may be several explanations for not seeing the anticipated inverse 
correlation between miR-155 and Smad5 in normoxia. Firstly, it may be that an 
additional stimulus such as hypoxia is necessary for this correlation to be 
manifested in PAFs. Alternatively, the choice of primary antibody may be 
relevant. Total p38 MAPK was used as the control for the Smad5 experiments.  It 
would be valuable to repeat the experiment and using a Total Smad5 antibody, to 
evaluate if the inverse correlation was only present in normoxia with regards the 
total levels of Smad5. 
 
As the links between hypoxia, PAFs and p38 MAPK are a core interest in the SPVU 
laboratory, a possible link between p38 MAPK and miR-155 was also explored.  The 
literature shows that upregulation of p38 MAPK is essential in the proliferation of 
PAFs, and that phosphorylation of p38 MAPK is increased in PAFs exposed to 
hypoxia. Furthermore, hypoxic hyperproliferation of PAFs can be prevented by 
inhibition of p38 MAPK [87, 89-91].  
 
Given the failure of KO MPAFs to hyperproliferate in hypoxia seen in this chapter, 
it was hypothesised that miR-155 KO would prevent p38 MAPK activation. This was 
indeed the observed outcome. The expected proliferative response to hypoxia of 
the WT MPAFs was confirmed. However, hypoxic phosphorylation of p38 MAPK was 
suppressed in the KO cells. Interestingly, even in normoxia, the KO cells appeared 
to have lower levels of phosphorylated p38 MAPK than their WT controls.  
 
These results proved promising not only in terms of demonstrating that microRNA-
155 manipulation could be used as a tool to better understand the pathobiology 
of pulmonary vascular remodelling, but also that miR-155 downregulation appears 
to confer a protective effect against the development of PH.  
 
As microRNAs are not universally conserved across species, it remained unknown 
whether the effect of miR-155 downregulation in mice could be replicated in 
another species. Furthermore, exploring whether the effects could be achieved 
pharmacologically would be necessary to determine if microRNA-155 
downregulation could have any therapeutic application. The experiments 
conceived to answer these problems formed the basis for the next chapter. 
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Chapter 4  
 
Exploration of pulmonary hypertension mechanisms 
and pathways after pharmacological knockdown of 
microRNA-155 in an in vitro rat model 
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4.1 Introduction 
 
The use of miR-155 manipulation as a tool to understand the mechanisms and 
pathways contributing to pulmonary vascular remodelling was demonstrated in a 
KO mouse model in Chapter 3. Knockout MPAFs failed to hyperproliferate in 
response to hypoxic stimulus, and hypoxia-mediated cellular migration was also 
abrogated by miR-155 knockout. Suppression of the hypoxia-driven p38 MAPK 
phosphorylation in PAFs was seen in the miR-155 KO cells, and there were 
enhanced levels of phosphorylated Smad5 in KO MPAFs in response to acute 
hypoxia. Overall this suggests that miR-155 downregulation protects against 
pulmonary vascular remodelling, possibly by suppressing activation of p38 MAPK 
signalling, and by restoring Smad5 levels. 
 
As described previously, the actions of microRNAs are complex. A single microRNA 
is capable of regulating many genes, and conversely a single gene can be 
influenced by many microRNAs [137]. Many thousands of microRNAs have been 
identified in humans alone, and whilst conservation of many of these (and their 
targets) across species is common, it is not universal. Even if a microRNA is widely 
conserved across species, the degree of expression can vary from species to 
species, and at various time points in the development of an organism [147]. 
Determining whether miR-155 was conserved across species would be important 
to determine if there was any potential human application for these results. 
 
Transgenic knockout is just one method of manipulating microRNA expression. 
Pharmacological alteration of microRNA levels has also been demonstrated. 
Enhanced expression of a microRNA can be achieved through use of a miR-mimic, 
which acts as a substitute for a downregulated microRNA. Suppression of 
microRNA levels can also be achieved by an antimiR, an oligonucleotide with a 
sequence complimentary to the microRNA being targeted. This therefore binds to 
the microRNA causing downregulation/knockdown.  
 
The potential therapeutic application of manipulating microRNA levels has been 
explored. Amongst the potential benefits of miRNAs is that their ability to target 
several genes within a network could enhance the therapeutic effect. Their 
relatively small size also lends them to ease of delivery into tissues. However, 
 86 
several challenges also exist. Targeting of the specific tissue where the microRNA 
imbalance exists can prove difficult, and issues therefore exist with “off-target” 
effects. Amplification of these “off-target” effects could also be caused by the 
ability of a single miRNA to suppress many genes. Additional concerns are also 
raised by the possibility of an immune response to the miR-mimic or antimiR in 
question, or the vector used to deliver it to its target tissue. 
 
Despite these potential challenges, several microRNAs are being investigated in 
human clinical trials. MicroRNA-122 is a liver specific miR that binds to the 5’-UTR 
of the hepatitis C virus genome and promotes the stability and accumulation of 
HCV RNA. Administration of Miravirsen, an antimiR-122 oligonucleotide, results in 
a prolonged decrease in HCV RNA in patients with chronic hepatitis C [179]. 
MIcroRNA-155’s association with haematological malignancy [170, 171] has also 
led to a clinical trial in humans. A phase 1 trial involving Cobomarsen, an animiR-
155 oligonucleotide, is currently underway to evaluate the effect of the antimiR 
on a form of Cutaneous T Cell Lymphoma [180]. 
 
Whatever the potential therapeutic uses of microRNA manipulation, their primary 
application in this thesis is as an exploratory tool. The key aims of this chapter 
are to validate and corroborate the results demonstrated in chapter 3, and to 
explore if they could be replicated both across species and by using a different 
technique for miR-155 downregulation. The hypothesis central to this is that an 
antimiR will be a successful alternative way to explore the effects of miR-155 
downregulation on pulmonary vascular remodelling, and that it will provide a 
protective effect against PH.  
 
The hypoxic model of PH will once again be utilised, however PAFs from rats will 
be used, and downregulation of miR-155 will be achieved through pharmacological 
knockdown with antimiR-155. 
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4.2 Relevant methods 
 
The techniques used in this chapter to evaluate the migration and proliferation of 
cells, and to examine protein expression are described in chapter 2. 
 
MicroRNA-155 knockdown was achieved through liposomal transfection of antimiR-
155. Lipofectamine 2000 was used as the transfection reagent and, after 
optimisation experiments were performed, a volume of 0.5µl per well in a 24 well 
plate (500µl total/well) or 3µl/well in a 6 well plate (3ml total/well) was used. 
AntimiR-155 was reconstituted with nuclease-free water per instructions supplied 
with the product, resulting in a 50µM working stock solution. 
Lipofectamine/antimiR-155 complexes were prepared at a 1:1 ratio using OptiMEM 
culture medium and an appropriate volume was then added to each well, such 
that the final concentration of antimiR-155 was 50nM. After 24 hours, the 
transfection process was halting by replacing the OptiMEM/antimiR-155 medium 
with standard DMEM culture medium containing the desired amount of serum. 
Experiments were then carried out as per standard protocols. 
 
To account for any potential impact on the experiment due to the actions of either 
the transfection reagent or the transfection process itself, experiments were also 
performed using a “Lipofectamine-only” control, and a random sequence 
“Negative Control” antimiR. 
 
The primary antibodies used for immunoblotting, along with their specific 
dilutions were as follows: 
• Phosphorylated p38 MAPK (1:500) 
• Total p38 MAPK (1:500) 
 
 
 
 
 
 
 88 
4.3 Results 
 
4.3.1 Pharmacological knockdown of microRNA-155 abrogates the 
hypoxic proliferative response in RPAFs. 
 
Abrogation of the hypoxic hyperproliferation of MPAFs by miR-155 knockout was 
demonstrated in Chapter 3. It was hypothesised that this could be replicated by 
pharmacological knockdown of miR-155 in rat PAFs. [3H]-Thymidine proliferation 
assays with increasing doses of serum were performed in normoxia and hypoxia 
using RPAFs treated with either antimiR-155, a Negative Control antimiR or 
Lipofectamine reagent alone.  
 
Figure 4-1 displays the results from these proliferation assays. 
 
Under normoxic conditions, the expected pattern of increasing proliferation with 
increasing doses of serum was seen. This was apparent not only in the cells treated 
with Lipofectamine alone, but also in the RPAFs transfected with the Negative 
Control antimiR, and also those treated with antimiR-155. 
 
The expected further proliferative response due to hypoxia was noted in the RPAFs 
exposed to Lipofectamine alone. This reached significance with the addition of 
both 1% and 5% FCS. 
 
Similarly, the hyperproliferative response to hypoxia was also seen in the RPAFs 
that had been transfected with the Negative Control antimiR. Once again, this 
was noted with 1% and 5% FCS. At the highest serum dose (10%) there was no 
significant difference between the normoxic and hypoxic Negative Control RPAFs, 
possibly due to cell contact inhibition. 
 
However, when the RPAFs that had been transfected with antimiR-155 were 
exposed to hypoxia, there was no additional proliferative response beyond the 
expected dose-dependent response to serum. This closely mirrored the results 
seen in the knockout MPAFs in chapter 3 and demonstrated that pharmacological 
downregulation has a similar effect to transgenic knockout. 
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Figure 4-1 Pharmacological knockdown of miR-155 ameliorates the enhanced proliferative 
response of RPAFs to hypoxia 
Normal RPAFs were treated with either Lipofectamine transfection reagent or a negative control 
antimiR and then cultured in normoxic conditions with the addition of [3H]-Thymidine for the final 
4 hours. The effect of stimulation with increasing doses was observed. Increased proliferation with 
higher doses of serum was noted, as indicated by increased incorporation of [3H]-Thymidine with 
radioactivity measured as CPM. When repeated in hypoxia an additional proliferative effect was 
noted, which reached significance at 1% and 5% serum, although the signal was lost at 10% serum, 
possibly due to contact inhibition. When the proliferation assay was repeated with RPAFs which 
had been treated with antimiR-155, the dose-dependent proliferative response was maintained. 
However, these antimiR-155 treated RPAFs did not demonstrate any additional response to 
hypoxia. Four experiments per condition were conducted, with values expressed as mean + SEM. 
Results were analysed using 2-way ANOVA with Bonferroni post-hoc analysis. *p<0.05. 
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4.3.2 Knockdown of miR-155 eliminates the migratory response of 
RPAFs to hypoxia 
 
Prevention of hypoxia-induced MPAF migration by miR-155 knockout was shown in 
Chapter 3. Transient downregulation of miR-155 in rat PAFs was hypothesised to 
produce the same effect. Scratch assays were performed on RPAFs that had been 
treated with either antimiR-155, a Negative Control antimiR, or Lipofectamine 
reagent alone, and subsequently exposed to either normoxia or hypoxia. 
 
Figure 4-2 displays the results. 
 
After 24 hours in normoxic conditions, the scratch created in the RPAFs treated 
with Lipofectamine alone persisted, with no degree of closure identified. When 
exposed to hypoxia however, migration of the Lipofectamine control RPAFs led to 
complete closure of the scratch, p<0.0001 (figures 4-2A). 
 
Similar findings were seen with the Negative Control antimiR (figures 4-2B). After 
24 hours in normoxic conditions, the scratch created in the NC RPAFs was still 
93.7% of its original width, showing minimal migration of the cells. However, after 
24 hours in hypoxia, migration of the NC RPAFs resulted in complete abolition of 
the scratch.  
 
However, knockdown with antimiR-155 prevented this hypoxia-driven migratory 
response of the RPAFs, with no significant difference in the width of the scratch 
after 24 hours, compared with the normoxic experiment (figure 4-2C).  
 
The width of each scratch was taken at 4 points. The graph in figure 4-2D 
summarises the results. 
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Figure 4-2 Pharmacological knockdown of miR-155 abrogates hypoxic migration of RPAFs. 
(A) RPAFs were cultured until they were near 100% confluent and the incubated for 24 hours with 
Lipofectamine 2000 transfection reagent. A vertical scratch was drawn through the monolayer of 
cells and photographed. The RPAFs were cultured for another 24 hours in either normoxia or 
hypoxia with fresh culture medium. The size of the residual scratch was then compared to the 
scratch at baseline. Measurements were taken at 4 equally-spaced points for each scratch. Whilst 
in normoxic conditions the scratch remains, the RPAFs exposed to hypoxia migrate to close the 
scratch entirely. (B) Scratch assay repeated with a Negative Control antimiR, introduced into 
RPAFs by liposomal transfection utilising Lipofectamine 2000. Once again, the scratch remains 
largely unchanged in normoxic conditions, but hypoxia results in closure of the scratch (C) RPAFs 
transfected with antimiR-155. After 24hrs in hypoxia, there is no significant difference in the 
degree of closure of the scratch compared with the cells exposed to normoxia. (D) Graphical 
representation of the change in scratch size for each condition after 24 hours, expressed as a 
percentage of the scratch size at 0 hours. Data presented as mean +/- SEM, analysed by 2-way 
ANOVA with Bonferroni post-hoc analysis, ****p<0.0001.  
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4.3.3 Hypoxia-induced p38 MAPK phosphorylation in RPAFs is 
ameliorated by treatment with antimiR-155. 
 
In Chapter 3 it was demonstrated that the hypoxia-induced phosphorylation of p38 
MAPK is lost in miR-155 KO MPAFs. It was hypothesised that this could be replicated 
by pharmacological knockdown of miR-155 in RPAFs. Transfection of RPAFs with 
either antimiR-155 or negative control antimiR, or treatment with Lipofectamine 
alone, was carried out.  Incubation in either normoxia or hypoxia was undertaken, 
both with and without serum. Immunoblotting of cell lysates for total and 
phosphorylated p38 MAPK was performed.  
 
Figure 4-3 shows these immunoblots along with a graph demonstrating the relative 
density of phosphorylated p38 MAPK compared with total p38 MAPK. 
 
When exposed to hypoxia, both the Lipofectamine-only RPAFs and those 
transfected with the Negative Control antimiR demonstrated a marked increase 
in the levels of phosphorylated p38 MAPK, compared to the normoxic controls.  
 
However, treatment of RPAFs with antimiR-155 ameliorated the effect of hypoxia, 
with significantly less p38 MAPK phosphorylation in the antimiR-155 RPAFs, 
compared to either of the control RPAF groups in hypoxia, p<0.0001. 
 
Densitometry was used to quantify these results (figure 4-3B). 
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Figure 4-3 Treatment with antimiR-155 abrogates the hypoxic phosphorylation of p38 MAPK 
in RPAFs 
(A) Liposomal transfection of RPAFs with antimiR-155 or a negative control antimiR using 
Lipofectamine 2000 transfection reagent was performed. A third group of RPAFs was treated with 
Lipofectamine transfection reagent alone. Half of the wells for each condition were then 
additionally stimulated with 5% FCS. Culture in either normoxia or hypoxia subsequently took place 
for 24 hours. Cell lysates were then immunoblotted for phosphorylated p38 MAPK or total p38 
MAPK. In hypoxic conditions, the pharmacological knockdown of miR-155 resulted in 
downregulation of phosphorylated p38 MAPK levels, compare to RPAFs treated with either the 
negative control antimiR or transfection reagent alone. Molecular weights: phosphorylated p38 
MAPK and total p38 MAPK both 43kDa. (B) Results quantified using densitometry, as density relative 
to total p38 MAPK. Data expressed as mean +/- SEM, Analysed by 2-way ANOVA with Bonferroni 
post-hoc analysis, ****p<0.0001. 
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4.4 Summary 
 
This chapter has demonstrated that the effects of miR-155 downregulation on 
mechanisms of pulmonary vascular remodelling and the p38 MAPK pathway can be 
replicated when an alternative method of manipulating microRNA levels is applied 
to a different species. This implies that the actions of miR-155, at least within the 
experiments carried out here, are conserved between mice and rats. Treatment 
of rat PAFs with antimIR-155 protects against the development of features seen 
in PH. 
 
As outlined in the general introduction, the proliferative response to hypoxia by 
PAFs is a key early development in pulmonary vascular remodelling [22, 23]. In 
this chapter, the expected hyperproliferative response to hypoxia was seen in the 
Lipofectamine-control RPAFs and the Negative Control antimiR RPAFs. However, 
this additional proliferation due to hypoxia was prevented in the RPAFs treated 
with antimiR-155. These results successfully show that transient knockdown with 
antimiR-155 can achieve the same results as those seen with knockout mice PAFs 
in Chapter 3, conveying a protective effect against PH.  
 
It was noted however that the radiation counts (i.e. the CPM) were generally lower 
in the RPAFs used in the knockdown experiments, compared with the KO MPAFs in 
Chapter 3. The exact reason for this is unclear. One potential explanation is that 
the RPAF cells may have been older, in terms of their passage stage, than the 
MPAFs from Chapter 3. They may also have been previously stored in liquid 
nitrogen and this could have had an influence on their proliferation. A further 
possibility is that the transfection reagent is causing a degree of cellular toxicity. 
This could perhaps have been clarified if the proliferation assay was also 
performed on a separate control group of RPAFs, in the absence of Lipofectamine. 
 
Muscularisation of previously non-muscularised vessels through the transformation 
of PAFs and their subsequent migration contributes to remodelling [28, 29]. Whilst 
the lipofectamine and negative control RPAFs migrated in response to hypoxia as 
expected in the scratch assays, this response was abrogated in the RPAFs 
transfected with antimiR-155. Once again, the results of Chapter 3 were 
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replicated in a different species using a different technique for miR-155 
downregulation. 
 
The Lipofectamine reagent did not obviously appear to negatively impact on the 
migration process in a way that would support the theory that it potentially 
contributed to the decreased radiation counts seen in the proliferation assays. 
However, it may be that the 24hr timeframe was still sufficient for the RPAFs 
which hadn’t been treated with antimiR-155 to overcome any impediment to their 
migration caused by the transfection reagent. Migration assays assessed at various 
time points between 0 and 24 hours may help clarify this.  
 
Upregulation of p38 MAPK pathways is seen in RPAFs following exposure to 
hypoxia, resulting in their proliferation. This hypoxic proliferation can be 
prevented by p38 MAPK antagonism [87, 89-91]. Results from Chapter 3 show that 
miR-155 KO prevents the hypoxic upregulation of p38 MAPK in MPAFs.  
Corroboration was therefore sought using this second model. Higher levels of 
phosphorylated p38 MAPK were detected in the Lipofectamine RPAFs and the 
Negative Control RPAFs as a result of acute hypoxia. This was prevented when 
RPAFs were treated with antimiR-155, mirroring results from the previous chapter. 
This once again suggests that the inhibition of PAF proliferation caused by miR-
155 downregulation is mediated by p38 MAPK. 
 
The interactions between hypoxia, PAFs and p38 MAPK are well-established and a 
key theme of the work carried out in our lab. The evidence obtained from these 
two in vitro models is that miR-155 also links into this relationship. MicroRNAs are 
known to be capable of influencing multiple genes in the same disease network. 
This raises the question as to what other PH-relevant genes might be influenced 
by miR-155 downregulation.  
 
The previously described links between Smad5 and miR-155 in haematological 
malignancy [167], combined with the involvement of Smad5 in TGF-b/BMP 
signalling, encouraged the investigation into a potential relationship between the 
two in PH. Chapter 3 confirmed the expected inverse correlation between Smad5 
and miR-155, with increased levels of phosphorylated Smad5 seen when MPAFs are 
exposed to acute hypoxia. 
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Attempts to replicate these results using RPAFs transfected with antimiR were 
made alongside the other work from this chapter, but no interpretable results 
could be obtained.  Non-specific binding of the primary antibody was repeatedly 
seen when the immunoblot was being probed. It was confirmed that the antibody 
in use was suitable for Western blots with mouse cells, but despite repeated 
efforts to optimise antibody concentrations an interpretable blot could not be 
produced. Similar results were noted with an antibody from a second 
manufacturer. Once again, the possibility of interference in the process by the 
transfection reagent or some other aspect of the transfection process is a 
potential explanation for these difficulties. 
 
Despite the issues experienced with linking miR-155 and Smad5 in the knockdown 
RPAFs, the results overall arguably fulfil the aims set out at the beginning of this 
chapter. The actions of miR-155, at least with regards to the measures of 
pulmonary vascular remodelling assessed here, have been shown to be conserved 
across at least two species. The use of pharmacological knockdown appears to 
have succeeded in that results in-keeping with the hypothesised effects of miR-
155 downregulation were achieved. These results therefore also provide further 
evidence for the hypothesis that miR-155 downregulation protects against PH. 
When combined with the results from the KO MPAFs, a compelling case for miR-
155’s role as a tool to understand pulmonary vascular remodelling in vitro has 
been built. 
 
The translation of in vitro findings into in vivo results is an essential next step in 
understanding disease pathobiology, and therefore establishing if research 
findings have any potential clinical application or therapeutic role in humans. 
Exploring the phenotypic effect of miR-155 knockout on mice exposed to chronic 
hypoxia was the natural progression of this project. Whether the cellular findings 
of Chapters 3 &4 would result in the prevention of PH in vivo was a core question.  
The experiments devised to answer this question are outlined in Chapter 5.  
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Chapter 5  
 
In vivo effects of microRNA-155 knockout on indices 
of pulmonary hypertension in an experimental 
mouse model 
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5.1 Introduction 
 
Chapters 3 and 4 have demonstrated that manipulation of microRNA-155 in two 
different in vitro models facilitates the investigation of processes and pathways 
that lead to pulmonary vascular remodelling.  
 
The proliferative and migratory effects of acute hypoxia on PAFs were lost in miR-
155 knockout mice. Similar results were shown by pharmacological knockdown of 
miR-155 in rat PAFs. Manipulation of miR-155 influenced signalling pathways that 
are known to be important in the development of pulmonary hypertension. In PH, 
the hypoxic phosphorylation of p38 MAPK is a key driver of fibroblast proliferation. 
This was ameliorated in the KO MPAFs and in RPAFs treated with antimiR-155. 
miR-155 knockout mouse PAFs in hypoxia also had enhanced levels of 
phosphorylated Smad5, compared with wild type counterparts. 
 
Therefore, downregulation of microRNA-155 in vitro appears to protect against 
pulmonary vascular remodelling by preventing PAF migration and proliferation, 
which may be due to ensuring adequate Smad5 levels (and therefore preserving 
normal TGF-b/BMP signalling) and by preventing the activation of p38 MAPK 
signalling. Overall, the apparent implication of this is that miR-155 
downregulation may prevent PH. 
 
Investigating whether in vitro findings translate to an effect in vivo is a key part 
not only of understanding the pathogenesis of a disease, but also in determining 
whether those findings may lead to the development of a potential treatment. 
The choice of animal model to use for an in vivo study is pivotal to help bridge 
the translation of a treatment “from bench to bedside”. The model must be 
validated and fit-for-purpose in order to address the clinical question. 
 
Several of the most commonly utilised animal models of PH have been described 
in the general introduction. The chronic hypoxic animal model is one of the most 
well recognised, and is firmly established in the SPVU laboratory. The basis behind 
this model is the finding that elevated pulmonary pressures and RVH develop in 
humans and animals that reside at high altitude [115, 116]. Acute hypoxia is a 
potent vasoconstrictor in the pulmonary circulation, however when hypoxia is 
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chronic it results in vascular remodelling [104], with HIF-1a mediating many of 
the cellular changes seen in response to hypoxia. The timeframe for this 
remodelling can vary between animals.  After exposure to hypobaric hypoxia for 
2 weeks, rats can develop elevated PA pressures, RV hypertrophy, muscularised 
and thickened distal vessels, and vascular pruning relatively quickly [117]. In mice 
however, hypoxia results in haemodynamic changes but remodelling can be less 
marked [118, 119]. 
 
Monocrotaline is a plant-derived toxin usually administered to rats to induce PH. 
Its effect is thought to be mediated by the direct toxic effect of its metabolites 
on lung tissue [122] with activation of pro-proliferative and anti-apoptotic factors, 
combined with dysregulated NO production [123, 124]. Neither the monocrotaline 
rat model nor the chronic hypoxic model result in formation of the plexiform 
lesions that are the hallmark of human IPAH. The Sugen/hypoxia model is a newer 
animal model which more closely reflects the human disease. This is not only 
because of the development of more extensive remodelling, including the 
presence of these plexiform lesions [129, 130], but also in the mechanism by which 
PH is induced. It involves the administration of a VEGF receptor-2 inhibitor 
(Sugen), followed by exposure to chronic hypoxia. This therefore fits with the 
current “multiple-hit” hypothesis thought to be important in the development of 
PH. 
 
Although there are limitations to its use, the simplicity of the chronic hypoxic 
model led to its application in this thesis. The aim of this chapter is to assess the 
effects in vivo of miR-155 knockout on the development of PH in the chronic 
hypoxic mouse model, the hypothesis being that miR-155 KO mice would be 
protected against hypoxic pulmonary hypertension and its consequences.  
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5.2 Relevant methods 
 
Hypoxic conditions were created using a hypobaric chamber. Mice were housed in 
the chamber for 14 days at a pressure of 550mbar, after a gradual reduction in 
atmospheric pressure over an initial 48-hour period. These conditions resulted in 
a reduction in oxygen concentration from approximately 21% to 10%. Temperature 
and humidity were maintained at constant levels, food and water were freely 
available, and a 12-hour light/dark cycle was imposed. Normoxic control animals 
were maintained adjacent to the chamber under the same conditions, but without 
depressurisation. 
 
An initial pilot study was undertaken. WT and KO mice were exposed to chronic 
hypoxia; however, comparison was only made to WT animals in normoxia due to 
the limited availability of KO animals.  
 
A larger study was subsequently performed, when KO animals under normoxic 
conditions were also included. Table 5-1 below displays the numbers of mice used 
in the main study. It outlines their characteristics based on whether they were WT 
or KO, whether they were exposed to hypoxia or normoxia, and their gender. It 
should be noted that the disparity between the number of animals used and the 
number of results obtained was occasionally influenced by technical issues. 
 
Wild Type n = 18 
Normoxia n = 7 
Male n = 3 
Female n = 4 
Hypoxia n = 11 
Male n = 6 
Female n = 5  
Knockout n = 13 
Normoxia n = 7 
Male n = 4 
Female n = 3 
Hypoxia n = 6 
Male n = 3 
Female n = 3 
 
Table 5-1 Characteristics of the mice used in the main in vivo study 
 
 
The methods for measuring haemodynamics and assessing RVH and vascular 
remodelling have been outlined already in Chapter 2. 
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5.3 Results 
 
5.3.1 Pilot study 
 
5.3.1.1 Right ventricular systolic pressure 
 
The right ventricle was catheterised via the right internal jugular vein using a 
Millar Mikro-Tip® PVR-1030 pressure-volume catheter. Figure 5.1 displays the RVSP 
results from the pilot study. 
 
The mean right ventricular systolic pressure of the WT mice kept in normoxia was 
23.62mmHg. When exposed to hypoxia, the mean RVSP rose to 38.64mmHg, a 
significant increase compared with the normoxic controls, p<0.0001.  
 
However, the mean RVSP of the knockout animals in hypoxia was significantly 
lower than the hypoxic WT controls at 31.91mmHg, p<0.005. 
 
 
 
Figure 5-1 MicroRNA-155 knockout reduces the effect of chronic hypoxia on RVSP in pilot data 
from an experimental mouse model. 
Wild type and knockout mice were exposed to hypobaric hypoxia for two weeks. Right ventricular 
systolic pressure was then measured. Wild type controls in normoxic conditions were also studied. 
MicroRNA-155 knockout conveys a protective effect against hypoxia, with lower RVSP than wild 
type animals in hypoxia (31.91mmHg vs 38.64mmHg). Data points indicate individual animals. 
Values are mean +/- SEM, analysed by one-way ANOVA with Bonferroni post hoc analysis, 
**p<0.005, ****p<0.0001  
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5.3.1.2 Right ventricular hypertrophy 
 
Hearts from the WT and KO mice that had been exposed to hypoxia were obtained. 
Right ventricular hypertrophy was assessed by Fulton’s Index, the ratio of the mass 
of the RV free wall to the LV plus septum.  
 
The mean Fulton’s Index of the WT mice after hypoxic exposure was 0.387. 
However, this was significantly lower in the hypoxia-exposed KO mice (0.345, 
p<0.05).  
 
The knockout mice therefore developed less RVH, as shown in figure 5-2. 
 
 
 
Figure 5-2 RVH is reduced in KO mice exposed to hypoxia versus WT controls in pilot data from 
an experimental mouse model. 
Heart were isolated from the mice. The right ventricular wall was separated from the left ventricle 
and septum. The ventricles were weighed after being blotted dry. The ratio of the RV to LV+S was 
calculated (Fulton’s Index). After hypoxic exposure, the KO mice had significantly less RVH than 
the WT mice, as demonstrated by a lower Fulton’s Index of 0.345 vs 0.387. Individual values are 
plotted and expressed as mean +/- SEM, analysed by unpaired t test. *p<0.05 
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5.3.2 Main study 
 
5.3.2.1 Right ventricular systolic pressure 
 
As in the pilot study, RVSP was measured by cannulating the right internal jugular 
vein and advancing a pressure-volume catheter into the right ventricle. 
 
Right ventricular pressure traces such as those shown in figure 5-3 were obtained. 
 
 
 
Figure 5-3 Right ventricular pressure traces obtained from mice 
The right ventricle was catheterised via the right internal jugular vein using a Millar Mikro-Tip® 
PVR-1030 pressure-volume catheter. Once a typical RV trace was obtained the readings were 
allowed to settle. Traces from top to bottom are normoxic WT, hypoxic WT and hypoxic KO. 
 
 
 
 
 
 
 
 104 
Figure 5-4 shows the RVSP results from the main study. 
 
Under baseline normoxic conditions, no statistically significant difference in RVSP 
was demonstrated between the wild type and knockout mice. Mean RVSP in the 
normoxic WT mice was 23.01mmHg versus 19.85mmHg in the KOs.  
 
When the wild type animals were exposed to hypoxia, mean RVSP was significantly 
higher than in the normoxic WT controls (38.89mmHg vs 23.01mmHg, p<0.0001). 
The knockout animals also demonstrated a rise in mean RVSP when exposed to 
hypoxia (31.61mmHg vs 19.85mmHg in the normoxic KOs, p<0.0005).  
 
When comparing the effect of hypoxia on the WT and KO mice, miR-155 appeared 
to convey a protective effect, as the mean RVSP of the KO hypoxic animals was 
significantly lower than that of the WT hypoxic animals (31.61mmHg vs 
38.89mmHg, p<0.05).  
 
When calculated as a percentage change in mean RVSP due to hypoxic exposure, 
the mean RVSP in the WT animals rose by 69%, vs a 59% increase in RVSP in the KO 
animals after hypoxia. This was calculated using the following equation: 
 
 
 
% change in mean RVSP   =   [mean hypoxic RVSP - mean normoxic RVSP]    x 100 
 
             Mean normoxic RVSP 
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Figure 5-4 MicroRNA-155 knockout mice exposed to hypoxia have a lower right ventricular 
systolic pressure than wild type controls. 
Wild type and knockout mice were either exposed to hypobaric hypoxia for two weeks, or 
maintained in normoxic conditions for the same duration. RVSP was then measured. There was no 
significant difference in RVSP between the WT and KO animals in normoxia (23.01mmHg vs 
19.85mmHg). Both the WT and KO animals showed an increase in mean RVSP when exposed to 
hypoxia (from 23.01mmHg to 38.89 mmHg, and 19.85mmHg to 31.61mmHg respectively). After 
exposure to hypoxia however, there was a significantly lower RVSP in the KO mice compared to 
the WT controls in hypoxia (31.61mmHg vs 38.89mmHg). Mean values for individual animals are 
plotted +/- SEM, n = 5-8 animals. Analysis by two-way ANOVA with post hoc Bonferroni test, 
*p<0.05, ***p=0.0005, ****p<0.0001 
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5.3.2.2 Right ventricular hypertrophy 
 
Fulton’s Index, the ratio of the mass of the RV free wall to the LV plus septum, 
was again used to assess RVH. Hearts were obtained from both WT and KO mice, 
after exposure to either normoxia or hypoxia. The results are shown in figure 5-5. 
 
There was no significant difference between the mean Fulton’s Index of the WT 
and KO mice that had been kept in normoxic conditions, 0.292 and 0.243 
respectively. 
 
Fulton’s Index was higher in the WT mice after hypoxic exposure, compared with 
their normoxic controls, demonstrating the development of RVH (0.364 vs 0.292, 
p<0.01). The KO animals however did not show a significant increase in Fulton’s 
Index after hypoxic exposure (0.303 vs 0.243 for the KO animals in normoxia). The 
development of RVH in these mice after two weeks of hypoxia therefore appeared 
to be attenuated by miR-155 knockout.  
 
Finally, whilst there appeared to be a trend towards a lower mean Fulton’s Index 
in the KO mice in hypoxia compared with the WT mice in hypoxia, this did not 
amount to a statistical significance (0.303 vs 0.364). 
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Figure 5-5 The effect of hypoxia on the development of RVH in mice is attenuated in microRNA-
155 KO, compared to WT controls. 
Knockout mice and wild type controls were exposed to either hypoxia or normoxic conditions for 
two weeks. Hearts were then isolated from the mice. The right ventricular wall was dissected from 
the left ventricle & septum, and after being blotted dry, the ventricles were weighed, and the 
ratio of RV/LV+S (Fulton’s Index) was calculated. Fulton’s index was not statistically different 
between the WT and KO mice in normoxia (0.292 vs 0.243). Exposure of the WT mice to hypoxia 
lead to the development of RVH, as demonstrated by a Fulton’s Index of 0.364 vs 0.292 in WT 
normoxic animals. Two weeks of hypoxic exposure did not cause significant RVH in the KO animals 
(Fulton’s Index 0.303 vs 0.243 in the KO normoxic controls). There appeared to be a lower Fulton’s 
Index in KO hypoxic mice compared with WTs in hypoxia, but this was not significant. Data points 
represent individual animals, n = 6-9 animals, mean +/- SEM.  Two-way ANOVA with post hoc 
Bonferroni test was performed, **p<0.01 
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5.3.2.3 Pulmonary vascular remodelling 
 
The method for evaluating pulmonary vascular remodelling has been described in 
chapter two. Vessels from WT and KO mice were obtained, after exposure to 
either normoxia or hypoxia. Pulmonary vascular remodelling was deemed as 
present if a vessel less than 80µm had a double elastic laminae for >50% of its 
wall’s circumference. The results are summarised in figure 5-6. 
 
Under normoxic conditions, there was no difference between the percentage of 
remodelled vessels seen in WT animals and the KO animals (6.71% vs 6.51%, 
respectively).  
 
Pulmonary vascular remodelling however was clearly demonstrated in the lungs of 
wild type animals exposed to hypoxia, with a mean of 13.75% of vessels 
remodelled, compared with 6.71% in the WT normoxic animals. 
 
Interestingly, only 7.06% of the KO vessels demonstrated remodelling after 
hypoxic exposure, similar to the results seen in the KO mice in normoxia, and 
significantly lower than the 13.75% of vessels in the WT hypoxia, p<0.0001. 
Knockout of miR-155 therefore appeared to protect against hypoxic vascular 
remodelling. 
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Figure 5-6 MIcroRNA-155 knockout prevents remodelling of pulmonary vessels in an 
experimental mouse model 
(A) Lungs were removed and 5µm sagittal sections were cut. These were stained with Miller’s 
Elastic stain and assessed microscopically in a blinded fashion. Vessels less than 80µm and not 
associated with an airway were analysed for remodelling, defined as the presence of a double 
elastic laminae for >50% of the vessel wall circumference. Representative examples of remodelled 
and non-remodelled vessels are displayed. Hypoxia promoted the remodelling of small non-
muscularised vessels in the wild type mice. miR-155 KO prevented this hypoxic vascular 
remodelling. Lung sections from three mice per group were studied, with three sections counted 
per mouse, and approximately 90 vessels per section. (B) Results presented graphically. Analysis 
by two-way ANOVA with post hoc Bonferroni test was performed, ****p<0.0001 
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5.4 Summary 
 
This aim of this chapter was to explore whether the encouraging in vitro results 
from Chapters 3 and 4 would translate to a demonstrable impact on in vivo indices 
of PH including haemodynamics and vascular remodelling. 
 
Downregulation of miR-155 in vitro resulted in attenuation of the hypoxia-driven 
proliferation and migration of PAFs, key contributors to vessel remodelling in PH 
[23, 29]. The p38 MAPK signalling pathway is a key driver of the PAF response to 
hypoxia, including proliferation [90, 91]. Activation of this pathway was prevented 
by miR-155 downregulation. Smad5 is a proven target of miR-155 and is essential 
for normal TGF-b/BMP signalling. The literature suggests a negative correlation 
between miR-155 and Smad5 [167], and therefore abnormal signalling through 
Smad5 due to the action of miR-155 would be anticipated. Chapter 3 showed 
elevated levels of Smad5 in miR-155 knockout MPAFs exposed to hypoxia, 
suggesting that miR-155 downregulation aids normal TGF-b/BMP signalling. 
 
This chapter’s results are in-keeping with the in vitro results and support the core 
hypothesis that miR-155 downregulation protects against PH. An initial pilot study 
demonstrated that miR-155 KO mice had lower RVSP after two weeks in hypoxic 
conditions, compared to wild type controls. The KO mice also had less hypertrophy 
of their right ventricles. These results, whilst promising, were limited by the lack 
of assessment of the baseline features of the KO mice, as there was no group of 
KO animals that had been kept in normoxic conditions.  
 
A further study was subsequently carried out, this time with analysis including KO 
mice in normoxia. The KO mice at baseline had an RVSP that was not significantly 
different to the WT controls, 19.85mmHg vs 23.01mmHg. In hypoxia, whilst both 
KO and WT animals developed a degree of pulmonary hypertension, the RVSP in 
the KO animals was lower than the WT animals (31.61mmHg vs 38.89mmHg, 
p<0.05) indicating a partially protective effect of miR-155 KO against the 
development of PH in mice.  
 
As would be expected, WT mice in the main study developed RVH as a result of 
hypoxic exposure. The KO mice in hypoxia however had a Fulton’s Index that was 
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not significantly different to their normoxic controls. This may indicate some 
degree of protection, although it’s also possible that a more prolonged exposure 
to hypoxia would have led to more significant remodelling of the right ventricle.  
 
Finally, the degree of pulmonary vessel remodelling was also assessed. The wild 
type animals developed clear evidence of remodelling after two weeks in hypoxic 
conditions. However, after two weeks in hypoxia, the KO animals had not 
developed any additional evidence of remodelling beyond their normoxic 
counterparts, which again suggests a protective effect against the development 
of PH and its consequences.  
 
Whilst the lack of remodelling in the KO hypoxia animals is in-keeping with the 
core hypothesis, the degree of remodelling seen in the WT mice in hypoxia is 
perhaps surprising to some degree. The generalised consensus from the literature 
is that whilst chronic hypoxic mice develop haemodynamic changes consistent 
with PH, the degree of vascular remodelling is less marked at two weeks than that 
seen in other animals, for example, chronic hypoxic rats [118, 119]. Therefore, 
whilst the detected difference in remodelling is encouraging, the reported 
literature should be borne in mind.  
 
It should be noted that in terms of absolute percentages, the difference in 
remodelled vessels in the hypoxic WT versus hypoxic KO mice from this study was 
13.75% versus 7.06%. Therefore 86.25% of vessels in the hypoxic WT mice were not 
remodelled. The literature also reports that different mouse strains respond 
differently to hypoxic stimulus. For example, the C57BL6 strain responds 
moderately, whilst other strains exhibit very little remodelling [181]. The degree 
of remodelling can also depend upon the age of the animal, with the lungs of 
younger animals being more susceptible to the effects of chronic hypoxia [35]. 
These factors should be considered when interpreting the results presented. 
 
In summary, use of the chronic hypoxic mouse model has demonstrated that the 
in vitro results from Chapters 3 & 4 could be translated to an in vivo effect. The 
results from this chapter have shown that miR-155 knockout has a protective 
effect against the development of pulmonary hypertension in a chronic hypoxic 
mouse model. 
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Chapter 6 
  
Discussion 
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6.1 Discussion of findings 
 
The impact of miR-155 downregulation on signalling pathways and pathological 
processes relevant to pulmonary vascular remodelling, and the subsequent in vivo 
effects, have been studied for the first time. Overall, a protective effect against 
the development of pulmonary hypertension appears to be conveyed by 
downregulation of miR-155. Manipulation of the levels of this microRNA has proven 
to be a useful tool in understanding the pathobiology of PAH. 
 
6.1.1 Downregulation of microRNA-155 influences signalling 
pathways important in pulmonary hypertension  
 
The TGF-b/BMP signalling superfamily regulates cardiovascular development and 
disease. In PH, it influences the proliferation, differentiation and migration of 
PAECs and PASMCs [36, 71, 72]. Mutations of receptors from this family are also 
key pathological influences in hereditary PAH and PAH related to HHT, for 
example BMPR2 mutations [77, 80, 81]. Links between miR-155 and TGF-b/BMP 
signalling exist, and a prominent example is the effect of miR-155 on Smad5, a 
key signalling intermediary of the superfamily. This has been explored in the 
context of Diffuse Large B-Cell Lymphoma, where miR-155 was found to directly 
control Smad5 [167] and promote dysregulated cell growth. The interaction 
between miR-155 and Smad5 in PH was therefore examined. 
 
Results from chapter 3 illustrate that under basal normoxic conditions the 
predicted inverse correlation between miR-155 and Smad5 was not seen. In fact, 
there was a signal that the KO MPAFs in normoxia had lower levels of 
phosphorylated Smad5. Hypoxia however had the effect of increasing Smad5 levels 
in both the WT and KO MPAFs, but this was significantly greater in the KO cells, 
which is in-keeping with the predicted inverse correlation. 
 
It is unclear exactly why the anticipated inverse correlation between miR-155 and 
Smad5 was not seen in normoxia. Perhaps a further stimulus such as hypoxia is 
required for this relationship to be manifested. Importantly, these results tell us 
about the activated state of Smad5 in these conditions rather that the total levels, 
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and perhaps using an additional primary antibody which detected total levels of 
Smad5 would clarify the picture. Given that miR-155 controls Smad5, I would 
expect to see increased levels of total Smad5 in the KO in both hypoxia and 
normoxia. Whether increased activation of Smad5 in the knockout model is 
protective against PH requires further clarification.  
 
Evidence of an effect on Smad5 levels in RPAFs treated with antimiR-155 was also 
sought alongside the work carried out for Chapter 4. However, an interpretable 
result could not be produced. The quality of the immunoblots for phosphorylated 
Smad5 in RPAFs treated with antimiR-155 was generally disappointing, with non-
specific binding of the primary antibody repeatedly seen. This was despite 
multiple attempts to optimise the experiment conditions and antibody 
concentrations, including using an antibody from a second manufacturer. The 
possibility of interference from the transfection reagent, or some other aspect of 
the transfection process, may be a potential explanation for this lack of results.  
 
The role of p38 MAPK as a key regulator of pulmonary vascular remodelling has 
been established. p38 MAPK is essential to the proliferation of PAFs in acute 
hypoxia, and is upregulated in PAFs from chronic hypoxic animals. Inhibition of 
p38 MAPK can prevent or reverse the hyperproliferative effect in these situations 
[89-91]. Endothelial dysfunction is also caused by hypoxic upregulation of p38 
MAPK, but this too can be reversed by p38 MAPK inhibition [93]. Signalling through 
p38 MAPK is activated in the context of PASMCs with BMPR2 mutations, due to 
ineffective Smad signalling. The effect of miR-155 knockout on p38 MAPK 
signalling was therefore an important area to consider. 
 
Results from this thesis reconfirm the activation of the p38 MAPK pathway in 
normal PAFs exposed to hypoxia. However, the downregulation of miR-155 
abrogates this hypoxic phosphorylation of p38 MAPK. This is the case in both KO 
MPAFs and RPAFs treated with antimiR-155. Given that p38 MAPK controls the 
hypoxic proliferation of PAFs and causes endothelial dysfunction, it can be 
inferred that miR-155 downregulation confers a protective effect against hypoxia-
driven remodelling via p38 MAPK. Once further insight had been gained into some 
of the influence miR-155 had on signalling pathways, it was relevant to examine 
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the effect that this would have on some of the cellular mechanisms which lead to 
pulmonary vascular remodelling. 
 
6.1.2 Mechanisms of pulmonary vascular remodelling are controlled 
by microRNA-155  
 
The pathobiology of pulmonary hypertension involves vasoconstriction, vessel 
remodelling, vascular pruning and thrombosis in situ [18]. The current treatments 
for PAH are aimed primarily at treating vasoconstriction and have minimal effect 
on remodelling. They offer functional benefit but improved survival is seen only 
with epoprostenol [14] and macitentan [15]. Therefore, treatments which target 
remodelling are vital for the future management of PAH.  
 
Dysfunctional cell proliferation, migration and apoptosis drives remodelling. 
Evidence of early adventitial remodelling and fibroblast proliferation has been 
noted in hypoxic animal models of PH [22], and hypoxic proliferation of PAFs has 
been shown to be greater than in other cell types [23]. The transformation of PAFs 
towards a myofibroblast phenotype occurs in hypoxia [27, 28], and these 
myofibroblasts migrate through the vessel wall resulting in the distal 
muscularisation of previously non-muscularised vessels [29-31]. Hypoxia-driven 
proliferation of PAFs has been proven to be conserved across species [86, 87].  
 
In this thesis, the effect of miR-155 downregulation on proliferation was examined 
in MPAFs and RPAFs. In both models, there was a dose-dependent proliferative 
response to serum, and normal PAFs had a hyperproliferative response when 
exposed to hypoxia. However, both genetic and pharmacological downregulation 
of miR-155 ameliorated the hyperproliferative response to hypoxia.  
 
Migration was assessed using scratch assays. Normal MPAFs and RPAFs responded 
as expected, with closure of the scratch confirming the migratory response of the 
PAFs to hypoxia. However, miR-155 knockout in mice or knockdown with antimiR-
155 in rat PAFs prevented this hypoxia-driven migratory response. 
 
Taken together, these results indicate that downregulation of miR-155 reduces 
pulmonary vascular remodelling by ameliorating the hypoxic proliferation and 
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migration of PAFs, and hence offers a protective effect against PH. This may be 
in part due to decreased p38 MAPK activity, given the results discussed above and 
by maintenance/restoration of Smad5 levels and therefore normal TGF-b/BMP 
signalling. The in vivo effect of altering these mechanisms was examined next.  
 
6.1.3 Pulmonary hypertension and miR-155: in vivo translation 
 
Compelling evidence for a beneficial effect of miR-155 downregulation in vitro 
has been revealed. Furthermore, given the different in vitro models utilised, the 
action of miR-155, at least with regards the signalling pathways and remodelling 
mechanisms outlined in this thesis, appears to be conserved across species. 
However, for the findings of biomedical research to have relevance to patient 
care, the translation of results from “bench to bedside” much be demonstrable. 
Evaluating the in vivo effects of miR-155 downregulation on indices of PH and 
pulmonary vascular remodelling was the vital next step in establishing the role of 
miR-155 in PH. The merits and disadvantages of various animal models of PH have 
been discussed in the introduction. The chronic hypoxic model was employed in 
this study. 
 
An initial pilot study was performed. Encouraging results were obtained, with a 
significantly lower RVSP found in the hypoxic knockout mice compared to their 
hypoxic wild type controls. RV hypertrophy was less marked in the hypoxic KO 
mice. However, understanding the full implications of miR-155 KO was limited by 
the lack of assessment of KO animals in normoxic conditions. 
 
A larger study was therefore undertaken, in order to corroborate results from the 
pilot, but also to evaluate baseline characteristics of the KO mice in normoxia. 
Once again, the effect of hypoxia on the KO mice was less marked than in their 
WT controls, as the KO mice had a significantly lower RVSP. At baseline, there was 
no significant difference between the WT and KO mice in terms of RVSP, 
suggesting that the protective effect of miR-155 KO against hypoxia is a true 
effect. 
 
When RV hypertrophy was assessed in the animals from the main study, the WT 
mice responded as expected to chronic hypoxia, with RVH evident at 2 weeks. In 
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the KO mice, significant RVH in response to hypoxia was not observed. This could 
suggest a protective effect against hypoxia or it could reflect the deficiencies of 
the chronic hypoxic model. It is unclear whether a more prolonged exposure to 
hypoxia may induce greater RVH in the KO animals.  
 
With regards to vascular remodelling in vivo, there was a clear difference in 
response to hypoxia between the WT and KO animals. Hypoxia resulted in 
increased vascular wall thickening after two weeks in the wild type animals, 
whereas this effect was not seen in the knockout mice, which demonstrated a 
similar degree of vascular remodelling as their normoxic controls. This finding is 
in-keeping with the other in vivo results and corroborates the main hypothesis. 
Intriguingly, the degree of remodelling in the WT animals was perhaps a little 
unexpected, as the consensus from the literature suggests that remodelling in less 
prominent in mouse models than other species. However, it has been noted that 
the degree of remodelling can vary depending on the mouse strain, as well as with 
the age of the animals [35, 181]. 
 
 
6.2 Limitations 
 
There are several limitations to the studies that were undertaken.  
 
Successfully examining the effect of miR-155 downregulation on Smad5 proved 
challenging, and this appeared to be due to problems with the primary antibody. 
Acceptable results were seen with the KO MPAFs, but obtaining interpretable 
results from the RPAFs treated with antimR-155 proved largely unsuccessful. 
Various antibodies from different companies were trialled at various 
concentration. Despite this non-specific binding remained a problem. A possible 
interaction between the primary antibody and the transfection reagent is among 
the possible explanations for this. 
 
With regards to signalling pathways, attempts were only made to evaluate Smad5 
and p38 MAPK.  The examination of more pathways or identified targets of miR-
155 that are known to be instrumental in PAH would add weight to this initial 
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data. Proving the existence of links to the likes of eNOS and IL-6, for example, 
would help corroborate my hypothesis. 
 
A general criticism of the in vitro work may come from the use of PAFs obtained 
from proximal pulmonary vessels. As PAH is generally a disease of the smaller 
distal vessels, results which more closely reflect the human disease may be seen 
if PAFs from distal vessels were used for the in vitro studies.  
 
In terms of the techniques used to examine remodelling processes, the scratch 
assay is relatively crude method of assessing migration, although it’s ease is 
attractive. A more robust technique may be the Transwell migration assay, where 
the ability of cells to pass through a membrane clarifies migratory from non-
migratory cells [182].  
 
The advantages and disadvantages of different animal models of PH has been 
discussed. A limitation of this work might be the choice of animal model used. 
The hypoxic mouse model develops haemodynamic changes but often lacks a 
significant degree of vascular remodelling. Chronic hypoxic rats develop a greater 
degree of remodelling, but still lack the classical plexiform lesions seen in human 
PAH. Use of a model such as SU5416/hypoxia in mice, which fits with the ‘multi-
hit’ hypothesis of PH, would perhaps better replicate human disease as 
exemplified by the presence of plexiform lesions [130]. Nonetheless, the fact that 
corroborating results from two different in vitro models was identified, with 
further confirmatory in vivo findings, suggests that the results obtained are valid 
and important. 
 
A further criticism of the in vivo work is that genetic knockdown is akin to a 
prevention study, examining if the development of PH could be avoided. Whilst 
this allowed exploration and understanding of the clinical phenotype of the KO 
mice, it’s relevance or application to patients is less relevant. A treatment study, 
where WT mice were allowed to develop chronic hypoxic PH and then treated with 
antimiR-155, would perhaps bear more similarity to the real-life experience of 
treating patients who have developed the disease. 
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6.3 Potential clinical application 
 
The purpose of biomedical research is ultimately to aid in the understanding of 
human disease and their treatments. The findings within this thesis, including the 
successful translation from cellular results to an in vivo response, are encouraging. 
It is obvious, however, that this does not necessarily guarantee that the results 
will translate to an effect in humans. An important first step will be exploring 
whether the results obtained in rodent cells can be replicated in human PAFs. 
 
As outlined previously, the biology of microRNAs can be complex. When it comes 
to their therapeutic application, there is the potential for great benefit. However, 
there are several anticipated/proven downsides. The actions of microRNAs are 
often not specific to the intended target tissue, creating off-target effects. This 
is especially in light of the ability of one microRNA to influence multiple genes. 
Problems with toxicity or immune responses may also arise either due to the 
therapeutic agent itself (e.g. an antimiR) or the vector used to get it to its target. 
 
Despite these issues, several clinical trials involving microRNAs in humans are 
underway. These include miR-122 and hepatitis C [149]; and miR-155 and 
cutaneous T-cell lymphoma [180]. Whilst the use of miR-155 as a therapy in 
pulmonary hypertension is many large steps away from being a possibility, the 
promising results seen in this thesis do indeed suggest the usefulness of this 
microRNA in PH research. Manipulation of miR-155 (and indeed several others) is 
likely to have further potential as a tool with which to explore PH pathobiology. 
 
 
6.4 Outstanding questions & future work 
 
The research outlined in this thesis has led to further important questions that 
should be addressed in order to further advance the understanding of miR-155’s 
role in PH and pulmonary vascular remodelling. The paramount question concerns 
the role of miR-155 in human PAH. Measurement of miR-155 levels in serum and 
whole lung tissue from PAH patients, and identifying if it was upregulated in small 
pulmonary vessels would indicate whether there was a potential translation from 
animal models to the human disease.  
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With regards to further in vitro work, replication of the experiments from chapter 
4 using normal human PAFs would be considered important. Examining the effect 
of antimiR-155 on the hypoxia-driven proliferation and migration of normal human 
PAFs would hopefully produce results in-keeping with the effects seen in Chapters 
3 and 4. Alongside this, exploring the effects of antimiR-155 on p38 MAPK and 
Smad5 in human PAFs would perhaps augment the evidence that these two 
pathways were implicated.  
 
Furthermore, human PAH-PAFs could be treated with a antimiR-155, with 
evaluation of signalling pathways and proliferative and migratory response. This 
would mark a step forward in understanding the role of miR-155 in PH by using a 
“reversal of disease” approach.  
 
Although only p38 MAPK and Smad5 have been examined in this work, the 
influence of miR-155 on other signalling pathways or causative stimuli should be 
addressed. In the general introduction, potential links between miR-155 and IL-6 
and eNOS were identified. These would be good starting points. However, further 
examination of miRbase or similar microRNA databases would likely identify other 
potential targets of miR-155 linked to PH that could be examined. 
 
Taken together, the above experiments should prove to be interesting lines of 
enquiry to pursue in order to develop this work further. 
 
 
6.5 Final comment 
 
This thesis has shown for the first-time direct links between miR-155 and 
pulmonary hypertension. Downregulation of miR-155 both in cells and animals 
conveyed a protective benefit, with evidence of less vascular remodelling and 
improved haemodynamics. Several potential signalling pathways are likely to be 
involved.  The manipulation of miR-155 levels has proven to be a useful tool in 
elucidating these pathways and remodelling processes. Further research into 
pulmonary hypertension through microRNA manipulation is warranted, in order to 
advance progress with new treatments aimed at reversing pulmonary vascular 
remodelling. 
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